Review

The Role of Non-Coding RNAs in the Pathogenesis of Parkinson’s Disease: Recent Advancement

Hanwen Zhang 1,†, Longping Yao 2,*,†, Zijian Zheng 1, Sumeyye Koc 3 and Guohui Lu 1,*

1 Department of Neurosurgery, First Affiliated Hospital of Nanchang University, Nanchang 330006, China; helenzhung1210@163.com (H.Z.); zijian.zheng@163.com (Z.Z.)
2 The Center of Neuroscience, Life Science Zurich Graduate School, University of Zurich, 8091 Zurich, Switzerland
3 Department of Neuroscience, Institute of Health Sciences, Ondokuz Mayas University, Samsun 55200, Turkey; sumeyyekoc0234@gmail.com
* Correspondence: loupe_yao@163.com (L.Y.); guohui-lu@163.com (G.L.);
† These authors contributed equally to this work.

Abstract: Parkinson’s disease (PD) is a prevalent neurodegenerative aging disorder that manifests as motor and non-motor symptoms, and its etiopathogenesis is influenced by non-coding RNAs (ncRNAs). Signal pathway and gene sequence studies have proposed that alteration of ncRNAs is relevant to the occurrence and development of PD. Furthermore, many studies on brain tissues and body fluids from patients with PD indicate that variations in ncRNAs and their target genes could trigger or exacerbate neurodegenerative pathogenesis and serve as potential non-invasive biomarkers of PD. Numerous ncRNAs have been considered regulators of apoptosis, α-syn misfolding and aggregation, mitochondrial dysfunction, autophagy, and neuroinflammation in PD etiology, and evidence is mounting for the determination of the role of competing endogenous RNA (ceRNA) mechanisms in disease development. In this review, we discuss the current knowledge regarding the regulation and function of ncRNAs as well as ceRNA networks in PD pathogenesis, focusing on microRNAs, long ncRNAs, and circular RNAs to increase the understanding of the disease and propose potential target identification and treatment in the early stages of PD.

Keywords: Parkinson’s disease; non-coding RNAs; neuroinflammation; microglia; dopaminergic neurons

1. Introduction

Non-coding RNAs (ncRNAs) are a cluster of unique transcripts that regulate cell function through various mechanisms that control gene expression at the transcriptional and post-transcriptional levels [1–4]. Although they are incapable of being transcribed as proteins to constitutive cell structures or modulate physiological processes, their specific regulatory mechanisms, such as competing for endogenous RNAs (ceRNAs), also are involved in the development of many diseases. It is widely acknowledged that some ncRNAs are closely associated with neurodegenerative diseases owing to their massive expression of transcripts and potential signaling pathways in the central nervous system (CNS), such as the substantia nigra striatum [5–7]. Notwithstanding such discoveries in ncRNAs, our understanding of the connection between ncRNAs and Parkinson’s disease (PD) pathogenesis is largely superficial. One possible mechanism is that ncRNAs participate in neuroinflammation mediated by microglial cells [8–12]. In recent years, many pathogenic factors have been associated with neurodegeneration in nigrostriatal dopamine neuron apoptosis or death caused by neuroinflammation [13–16] (Figure 1). These factors are potential targets that interfere with the disease process of PD [8,17,18]. In this review, we primarily concentrate on miRNAs, lncRNAs, and circRNAs, as well as the details of their roles and potential regulatory mechanisms in the pathogenesis of PD.
primarily concentrate on miRNAs, lncRNAs, and circRNAs, as well as the details of their roles and potential regulatory mechanisms in the pathogenesis of PD. Some underlying mechanisms, such as competing endogenous RNA (ceRNA), have been confirmed, but many potential mechanisms are not fully understood.

Figure 1. The self-propelled deterioration cycle in PD. Microglia are active under the pathogenic conditions of PD and release anti-inflammatory cytokines to heal the tissues, saving neurons from apoptosis or death. Continuous stimulation of pathogenic factors, on the other hand, increases the number of toxic phenotypes of microglia, resulting in the release of a significant number of inflammatory cytokines such as TNF-α, IL-1, iNOS, and IL-6, all of which lead to neuronal damage. Furthermore, damaged or dead DA neurons can directly activate microglia, resulting in an increase in reactive oxygen species (ROS) and pro-inflammatory cytokines. Microglia activation and DA neuronal injury thus form a self-propelled degeneration cycle in PD.

2. ncRNAs

2.1. Introduction

Non-coding (ncRNAs) RNAs are broadly defined as a cluster of RNA transcripts that are incompetent to code proteins. In recent years, as the development of sequence and structure analysis has accelerated, techniques such as next-generation sequencing have deepened our understanding of ncRNAs. Most genomes can be converted into RNAs. However, only 2% of that can ultimately be translated into proteins. Thus, RNAs are classified into two types, coding RNA and ncRNAs; ncRNAs are further divided into structural and regulatory ncRNAs. From an evolutionary perspective, structural ncRNAs are conserved and expressed in almost all species of creatures, including plants, yeast, viral and procaryotic organisms, and the housekeeping genes for these creatures are rRNA and tRNA. Concurrently, the conservation of regulatory ncRNAs is poorer than that of structural ncRNAs, including small ncRNAs such as miRNAs, medium-long ncRNAs, and long non-coding RNAs (lncRNAs). This observation is consistent with the conclusion that ncRNA explains the complexity of multicellular organisms. Although ncRNA was initially recognized as “dark transcriptome” or “genomic dark matter” [19,20], an increasing number of reports has demonstrated that ncRNA exhibits a crucial role in regulating cellular pathways and functions on both genetic and epigenetic levels. For instance, ncRNAs can guide DNA synthesis and genome rearrangement and protect genes from exogenous nucleic acids [3]. The mechanism of ncRNAs has been a topic of interest in recent years. Some underlying mechanisms, such as competing endogenous RNA (ceRNA), have been confirmed, but many potential mechanisms are not fully understood.

2.2. ncRNAs in PD

The brain contains several types of ncRNAs, including miRNA, lncRNA, circRNA, and piwiRNA, which play essential roles in neuronal growth, differentiation, organization, operation, and protection of the CNS throughout the life cycle. Based on fundamental exper-
imental studies on the potential mechanisms, insights from such research offer substantial proof that ncRNAs can regulate diverse signaling pathways associated with neurodegeneration, including cell apoptosis, mitochondrial dysfunction, oxidative stress, altered protein handling, neuroinflammation, and specific protein aggregation [21–24]. Some lncRNA, miRNA, and circRNA can also participate at the transcriptional and post-transcriptional levels through the ceRNA pathway to regulate target proteins and thus affect neurodegeneration. Others can directly regulate related proteins, and exosomes secreted by neurons can control some proteins. Although the molecular mechanism of PD has been thoroughly researched, the occurrence and promotion mechanisms of PD remain unclear.

3. LncRNA

3.1. Introduction

Long non-coding RNA (lncRNA) refers to enormous RNA families defined by a length over 200 nucleotides, limited protein-coding potential, and no detectable open reading frames, which are necessary for protein-coding potential. Meanwhile, lncRNAs are considered to serve as a cryptic, but critical, layer in the genetic regulatory code associated with diverse physiological and pathological responses, dysfunction is closely related to the occurrence of diseases [25].

3.2. lncRNAs in the Pathogenesis of PD

LncRNAs have received increased research focus, especially regarding neurodegeneration in brain function and CNS disorders. Many lncRNAs have been reported to be abnormally expressed in the cytoplasm in PD. For example, Kraus performed a comprehensive analysis of the expression levels of 90 well-annotated lncRNAs in 30 brain specimens derived from 20 patients with PD and 10 controls as a preliminary report on the significance of lncRNAs in PD. They found that the H19 upstream conserved 1 and 2 is significantly downregulated in PD. Additionally, lincRNA-p21, LINC-PINT, metastasis-associated lung adenocarcinoma transcript 1 (Malat1), small nucleolar RNA host gene 1 (SNHG1), and tiny non-coding RNAs are significantly upregulated [26]. Additionally, microarray analysis has reported that the upregulation of lncRNAs HOTAIRM1 and AC1131056.3 and downregulation of lncRNA XIST may contribute to PD pathogenesis through dopaminergic neuron injury [23,27]. M’arki et al. predicted that lncRNA BCYRN1 SNPs rs13388259 is associated with PD because it is located close to the binding site of the transcription factor HNF4A, which is upregulated in peripheral blood [28].

Additionally, abnormal deposition of α-syn has been implicated in the function of lncRNAs. lncRNA NEAT1, previously known as an oncogene in malignant tumors, was found to accelerate α-syn aggregation and simultaneously promote neuronal apoptosis in MPTP-induced PD mice [29]. Lin et al. found that lncRNA G069488, RP11-142J21.2 and AC009365.4 corresponded to α-syn deposition in α-syn oligomer-induced cells using microarray analysis [21].

Autophagy plays a significant role in PD pathogenesis. The disharmony of autophagy is significantly associated with α-syn aggregation. L1CAM, an exosome derived from neurons, has been reported to correspond to the autophagic-lysosomal pathway, at least partly participating in autophagy. Zhou et al. demonstrated that linc-PIU3F3 exerted a positive regulatory effect on α-syn in L1CAM [30]. Similarly, the α-syn pathogenetic aggregation, lncRNA-T199678 has been identified to serve as a sponge of miR-101-3p to relieve dopaminergic neuron injury [31]. Additionally, Huang et al. and Quan et al. recruited patients with PD and healthy controls to evaluate the expression of lncRNA MEG3, which is downregulated in patients with PD. They found that overexpression of MEG3 protected MPP+ SH-SY5Y cells from apoptosis by boosting LRRK2 expression [32,33].

Another pathogenesis in which lncRNAs participate is that of neuroinflammation. Together, lincRNA-p21 and miR-181/PKC-δ forms a double-negative feedback loop that facilitates sustained microglial activation and the deterioration of PD [34]. A recent study showed that overexpression of lncRNAAGAS5-activated microglia promoted NLRP3 ex-
pression and consequently improved neuroinflammation in PD by sponging the miR-223-3p/NLRP3 signaling pathway [35].

Abnormal expression of lncRNAs in the cytoplasm has been shown to be associated with apoptosis. Lnc-MKRN2-42:1 in exosomes has been reported to contribute to the pathogenesis of PD by next-generation sequencing and bioinformatics analysis [36]. LINC-PINT, a cancer-promoting gene, has recently been found to exert a neuroprotective role in PD [37], and lncRNA GAS5 is expressed differently in the hippocampus region of young and old mice and is associated with cell proliferation and apoptosis [38]. Additionally, lncRNA UCA1 and lncRNA HOATAIR promote caspase-3 activation and enhance apoptosis in the MPP+-induced cell model by respectively upregulating the expression of SNCA and LRRK2 [39,40] (Table 1) (Figure 2).

Table 1. lncRNA in pathogenesis and neuroinflammation of PD.

| Species of lncRNAs | Changes in lncRNAs Levels in PD's Brain, CSF and Serum | Changes in lncRNAs Levels in Genetic Mouse Models and Cell Models for PD | Response of lncRNAs to PD “Triggers” In Vitro (Exposure Time if Relevant) | lncRNAs Target Genes (Experimentally Validated) |
|------------------|-------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------------------------|-----------------------------------------------|
| H19              | ↓/PD’s brain [26]                                      |                                                                 | ↑/apoptosis                                                | MAPK, Jak-STAT                                |
| lincRNA-p21      | ↑/PD’s brain [26]                                      |                                                                 | ↑/apoptosis                                                | MAPK, Jak-STAT                                |
| LINC-PINT        | ↑/PD’s brain [26]                                      |                                                                 | ↑/neuroinflammation                                        | MAPK, Jak-STAT                                |
| Malat1           | ↑/PD’s brain [26]                                      |                                                                 |                                                      |                                               |
| SNHG1            | ↑/PD’s brain [26]                                      |                                                                 |                                                      |                                               |
| HOATAIRM1        | ↑/PD’s circulating leukocytes [23]                     | ↑/neuroinflammation                                                |                                                      |                                               |
| AC1131056.3      | ↑/PD’s circulating leukocytes [23]                     | ↑/neuroinflammation                                                |                                                      |                                               |
| XIST             | ↓/PD’s serum [27]                                      | ↓/apoptosis                                                        | hsa-miR-133b/IGF1R                                         |                                               |
| PART1            | ↓/PD’s serum [27]                                      | ↓/apoptosis                                                        | hsa-miR-133b/IGF1R                                         |                                               |
| rs13388259       | ↓/PD’s serum [28]                                      | ↓/apoptosis                                                        |                                                      | HNF4A                                         |
| NEAT1            | ↑/MPTP induced CSF/BL/6 mice [29]                      | ↑/α-synuclein aggregation                                          | ↑/apoptosis                                                | Bax/Bcl-2 caspase-3                           |
| G069488          |                                                      | ↑/α-synuclein aggregation                                          |                                                      |                                               |
| RP11-142J21.2    |                                                      | ↑/α-synuclein aggregation                                          |                                                      |                                               |
| AC1009355.4      |                                                      | ↑/α-synuclein aggregation                                          |                                                      |                                               |
| Linc-POU3F3      | ↑/L1CAM exosome in PD plasma [30]                      | ↑/α-synuclein aggregation                                          | ↑/autophagy                                                | GCase                                         |
| MEG3             | ↓/PD’s serum [35]                                      | ↓/MPP+ treated SH-SY5Y cells [32,33]                               | ↓/apoptosis                                                | LRRK2                                         |
| HOXA-AS2         | ↑/PD’s PBMCs [41]                                      | ↑/neuroinflammation                                                | ↓/PGC-1α ↑/PRC2                                           |                                               |
| MALAT1           | ↑/MPTP-induced PD mice ↑/LPS/ATP-induced microglia cells [42] | ↑/inflammasome activation ↑/reactive oxygen species (ROS)         | ↓/Nrf2                                                     |                                               |
| RMST             | ↑/brain SN of PD rats                                  | ↑/oxidative stress                                                | ↑/apoptosis                                                | TLR/NF-Kb                                     |
| Lnc-MKRN2-42:1   | ↑/PD’s serum [36]                                      |                                                      |                                                      |                                               |
Table 1. Cont.

| Species of lncRNAs | Changes in lncRNAs Levels in PD’s Brain, CSF and Serum | Changes in lncRNAs Levels in Genetic Mouse Models and Cell Models for PD | Response of lncRNAs to PD “Triggers” In Vitro (Exposure Time if Relevant) | lncRNAs Target Genes (Experimentally Validated) |
|-------------------|------------------------------------------------------|------------------------------------------------------------------|------------------------------------------------------------------------|-----------------------------------------------|
| LINC-PINT         | ↑/PD’s serum [37]                                     | ↓/cellular survival ↑/oxidative stress                           |                                                                        |                                               |
| UCA1              | ↑/PD mouse brain                                      | ↑/MPP+-induced SH-SY5Y cells [39,40]                             | ↑/caspase-3 activation ↑/apoptosis                                       | ↑/SNCA                                         |
| HOTAIR            | ↑/PD mouse brain                                      | ↑/MPP+-induced SH-SY5Y cells [41]                                |                                                                        | ↑/LRRK2                                        |
| GAS5              | ↑/old mouse brain                                     | ↓/cell cycle progression ↑/apoptosis                             |                                                                        |                                               |

Figure 2. LncRNA representative signal pathways involved in Parkinson’s disease pathogenesis and neuroinflammation. Straight arrows indicate lncRNAs regulate gene (protein) expression in PD pathogenesis. Two consecutive arrows mean that there may be other participants in the process.

3.3. lncRNAs in the Neuroinflammation of PD

The remaining abnormally labeled lncRNAs have been demonstrated to mediate inflammatory responses in other diseases, but they seem to be under investigation in the inflammatory pathogenesis of PD. SNHG1 promotes neuroinflammation in the pathogenesis of PD by modulating the miR-7/inflammasome pyrin domain-containing 3 (NLRP3) pathway. Downregulation of SNHG1 suppresses the activation of microglia and NLRP3 inflammasome, as well as DA neuron loss in the midbrain substantia nigra, pars compacta (SNpc) in MPTP-induced PD mice [43]. Additionally, Wang et al. Found that SNHG1 facilitates neuronal injury by modulating miR-181a-5p/CXCL12, miR-125B-5p/MAPK1, miR-216A-3p/Bcl-2, miR-221/222/p27/mTOR, miR-15b-5p/GSK3β, and the miR-153-3p/PTEN/ AKT/mTOR axis in neuroblastoma cells [22,44–49]. HOXA-AS2 was considerably upregulated in peripheral blood mononuclear cells of patients with PD and showed a reversible regulatory relationship with PGC-1α expression. HOXA-AS2 promotes neuroinflammation by accelerating the conversion of microglia to an anti-inflammatory M2 phenotype [41].
Moreover, the lncRNA HOXA11-AS was overexpressed in an animal model of PD: MPTP (+)-induced NLRP3 inflammatory expression and LPS-induced microglial activation in a PD cell model was enhanced by HOXA11-AS and FSTL1 upregulation and/or miR-124-3p knockdown [50]. Moreover, activating the inflammasome and producing ROS are important mechanisms by which MALAT1 is involved in the pathogenesis of PD by restraining Nrf2 expression in both microglial cells and mouse models [42]. Inhibition of lncRNA RMST mitigated oxidative stress and neuronal apoptosis, augmented the expression of TH and SYN, and induced neuronal impairment through the TLR/NF-κB signaling pathway [51]. miR-625/TRPM2 is another neuroinflammation-related signaling pathway that promotes oxidative stress via Inc-p21, leading to PD development [52] (Table 1) (Figure 2).

3.4. Circulating lncRNA in the Pathogenesis and Neuroinflammation of PD

Circulating lncRNAs have been recently reported to be dysregulated in the circulation of patients with PD, which indicates that the expression level of circulating lncRNAs might be considered a biomarker for PD. Kasra et al. profiled lncRNA expression in the peripheral blood of patients with PD and healthy controls using qRT-PCR. HULC, PVT1, MEG3, SPRY4-IT1, LINC-ROR, and DSCAM-AS1 lncRNA expression levels were measured. HULC and PVT1 levels were lower in patients with PD, while MEG3, SPRY4-IT1, LINC-ROR, and DSCAM-AS1 levels were higher. HULC and PVT1 have been shown to regulate apoptosis [53–55]. These results indicate the potential role of circulating lncRNAs as treatment markers for PD. However, none of these lncRNA expressions were related to patient age, disease stage, Mini-Mental State Examination scores, or Unified Parkinson’s Disease Rating Scale scores [56].

Previous studies have shown that nuclear factor-κB (NF-κB) regulates the activity of inflammatory intermediates during inflammation and oxidative stress, which contribute to the neurodegenerative process in PD [57,58]. Thus, to appraise their possible application as disease markers, Ghafouri-Fard et al. identified circulating lncRNAs involved in the modulation of NF-κB signaling in the circulation of patients with PD versus healthy individuals, including CEBPA, ATG5, PACER, DILC, NKILA, ADINR, DICER1-AS1, HNF1A-AS1, CHAST, and H19. PACER and HNFA1-AS were lower, while DILC, CEBPA, ATG5, and H19 were higher. CEBPA, DILC, and ATG5 were determined to be the most appropriate markers. These results provide evidence for the participation of NF-κB-related lncRNAs in the pathogenesis of PD [59].

4. microRNA (miRNA)

4.1. Introduction

miRNAs are small ncRNA molecules containing approximately 22 nucleotides that are initiated from pre-miRNAs transcribed by RNA pol II [60–63] (Figure 2). It could play a complex role in regulating transcription of multiple genes via combining with Argonaunt and other proteins into the RNA-Silencing Complex. This complex binds to mRNA and promotes post-transcriptional regulation by promoting the degradation of mRNA and subsequently inhibiting the expression of target genes [64,65]. miRNAs are well-known for cancer pathogenesis. However, many miRNAs are also pivotal regulators of normal CNS function by regulating neuronal proliferation and differentiation [66,67]. Additionally, the altered expression of miRNAs could contribute to neurodegeneration in neurological disease [68], including Alzheimer’s disease [69], amyotrophic lateral sclerosis [70], and frontotemporal dementia [71]. Therefore, identifying the impact of miRNA on PD is necessary (Figure 3).
miR-218-5p ↓/brain ↓/brain SN of PD rats ↑/apoptosis ↑/ROS ↑/NF-κB ↑/LASP1 [122]

miR-223 ↓/brain [72] ↓/serum ↓/saliva

miR-291 ↓/ROCK2 [122]

miR-326 ↓/brain ↑/apoptosis ↑/iNOS ↑/α-syn ↑/XBP1 [94,95] ↑/MAPK/KLK7 [46]

miR-331-5p ↓/CSF [103]

miR-342-3p ↑/C57BL/6 mice ↑/apoptosis ↓/PAK1 ↓/Wnt [123]

miR-380-3p ↑/N2a ↑/apoptosis ↓/Sp3 [96]

miR-486-5p ↑/colonic biopsies [76]

miR-599 ↓/brain ↑/LERK2 [80]

hsa-miR-626 ↓/CSF [100]

hsa-miR-19b-3p ↑/CSF [124]

Figure 3. The targeted regulation mechanism of miRNA and competitive endogenous RNAs (ceRNAs). (A) The regulation function of miRNAs is to target mRNA molecules with complementary sequences. As a result, the genes can be silenced by cleavage of the mRNA strand. (B) LncRNA and circRNA combine with miRNA so that mRNAs are protected from degradation and consequently translate to proteins.

4.2. microRNA in the Pathogenesis of PD

The abnormal expression of miRNAs is attributable to the development and progression of numerous diseases. Similarly, in patients with PD, the serum and striatal brain tissue and DA neurons from the SNpc demonstrated dysregulation of miRNA expression. On the one hand, some miRNAs were downregulated in PD; for instance, miR-153 and miR-223 were observably decreased in the saliva, serum, and brain of patients with PD compared to normal controls [72]. An exciting result showed that the expression levels of miR-132-3p, miR-146-5p, and miR-29b were significantly decreased in the serum of patients with severe PD compared to those in regular patients with PD and the healthy group, which indicated that the levels of these miRNAs were related to memory performance and cognition [73,74]. In addition, the levels of other miRs were improved in PD, and the level of miR-132 was elevated in the PD serum compared to that in healthy controls [75]. One investigation found that miR-486-5P expression was significantly enriched in colonic biopsies from patients with PD compared to that in the control group, offering a potential gene treatment target for PD [76]. Besides miR-132 and miR-486-5P, miR-105-5p and miR-195 are similarly expressed at higher levels in idiopathic PD than in healthy groups [65,77]. miR-29c expression is notably increased in Turkish patients with PD [78]. Dysregulated miRNA expression profiles indicate potential therapeutic targets for PD. In addition to dysregulated miRNAs in the cytoplasm, an exploratory study showed that miR-34a-5p expression was markedly upregulated in small extracellular vesicles from patients with PD compared to that in normal subjects [79].

As miRNA dysregulation may participate in PD pathogenesis, we conclude the specific mechanism of miRNAs in reference to PD. Excessive activation leads to autophagy failure, thereby increasing the aggregation of α-syn. MiR-599 was found to serve as a negative regulator of LRRK2, and when microRNA-599 is expressed, LERK2 is highly expressed in cell and animal models [80]. In addition, MiR-155-5p has been reported to be expressed heavily in patients with PD [81] and modulating α-synuclein-triggered inflammatory
response in a PD mice model [82]. This result was also found in PD mice treated with RA, a neuroprotective substance in PD [83]. Meanwhile, miR-153/miR-223 was shown to be downregulated by overexpression of HO-1 in stressed astroglia to promote α-syn production and toxicity [84]. In addition, upregulation of miR-204-5p also contributes to the increase in α-syn and other neurotoxicity protein aggregation via inhibition of the Dyrk1A-mediated ER stress and apoptosis cascade [85].

Research findings have also shown that competitive endogenous RNAs (ceRNAs) networks regulate mitochondrial dysfunction and lead to loss of dopaminergic neurons, inducing loss of dopaminergic neurons. Failure to eliminate damaged mitochondria leads to the accumulation of dysfunctional mitochondria and DA neuronal impairment [24,86], which was verified to partially correspond to the increased amount of miR-146a bound to NF-kB via repression of Prkkn expression [87]. Several miRNAs have been demonstrated to target PINK1S, which is vital for mitochondrial autophagy, such as miR-27a and miR-27b. Kim et al. found that miR-27a/27b can bind to the 3′ untranslated region (3′UTR) of PINK1 mRNA to inhibit PINK1 function and mitophagy. Predominantly, miRNA-144 induces microglial autophagy and inflammation following intracerebral hemorrhage [88]. In contrast, miR-144 and its target gene β-amyloid precursor protein regulate MPTP-induced mitochondrial dysfunction [89].

Injured autophagy in dopamine neurons leads to α-syn in PD. miR-128 was previously predicted to be linked to Tfeb, a critical gene involved in autophagy and lysosome phagocytosis, and its overexpression could rescue α-syn toxicity in midbrain neurons [90]. In brain autopsies of patients with PD, the Tfeb content was highly decreased in the midbrain. The downregulation of miR-29c-3p has been reported in the SNpc DA neurons of PD mice and may be accompanied by autophagy by inhibiting TET2 [91]. Lack of IFNB/interferon-β blocked neuronal autophagy associated with impaired autophagosome degradation, leading to the accumulation of various neurotoxic aggregation-prone proteins, and an exciting study observed that miR-1 could play a pivotal role in the loss of IFNB-induced impaired autophagy by targeting TBC1D15/Rab7 [92,93]. By inhibiting the expression of Xbp1, miR-326 overexpression enhances autophagy of neurons and suppresses iNOS immune-positive cells through the JNK signaling pathway in in vitro and in vivo PD models [94]. In addition to inhibiting autophagy, miR-326 suppresses apoptosis and improves the proliferation of dopaminergic neurons by repressing the MAPK/klk7 signaling pathway [95].

Apoptosis is the terminal outcome of dopaminergic neurons in patients with PD. The mechanisms described above ultimately contribute to apoptosis. MiR-380-3p suppressed cell proliferation and aggravates PQ-induced PD, and the potential tool is that miR-380-3p block the translation of Sp3 mRNA [96]. The upregulation of miR-15b-5p represses the rate of apoptosis and caspase-3 activity in the MPP (+)-induced SH-SY5Y cell model and the MPTP-induced mouse model by downregulating the Akt3-mediated Gsk-3β/β-catenin signaling pathway [97]. MiR-185 was downregulated in a PD model, and its restoration mitigated oxidative stress by targeting IGF1 to invoke the PI3K/AKT signaling pathway [98].

In addition to experimental validation, several studies have conducted computational prediction to propose evidence of the participation of miRNAs in PD pathogenesis; Ssg15, Rrm2, Fbxw11, Foxm1, and the miR-181 family were found to be aberrantly expressed in PD [99]. Hsa-miR-626 was significantly decreased in the cerebrospinal fluid of patients with PD [100]. Another microarray analysis showed that hsa-miR-19b-3p levels were higher than healthy [101]. Additionally, miR-7-5p, miR-331-5p, miR-145-5p, hsa-miR-335-5p, has-miR-3613-3p, hsa-miR-335-5p, and miR-335-5p/miR-3613-3p/miR-6865-3p were verified to have diagnostic value for PD using other microarray analyses [102,103]. Although many miRNAs have been found to increase or decrease in patients with PD, the specific mechanism of action has not yet been elucidated. However, some studies have identified new potential therapeutic targets [104] (Table 2) (Figure 4).
Table 2. microRNAs in PD pathogenesis.

| Species of miRNAs | Changes in miRNA Levels in PD’s Brain, CSF and Serum | Changes in miRNA Levels in Genetic Mouse Models and Cell Models for PD | Response of miRNA to PD “Triggers” In Vitro (Exposure Time if Relevant) | miRNA Target Genes (Experimentally Validated) |
|-------------------|----------------------------------------------------|-------------------------------------------------------------------|-----------------------------------------------------------------------|-----------------------------------------------|
| miR-1             | ↓/CSF                                              | ↓/autophagy                                                      | ↑/TBC-7 ↑/TBC1D15                                                   | [92,93]                                       |
| miR-1-3p          |                                                    |                                                                   | FAIM [105]                                                          |                                               |
| miR-15b-5p        | ↓/SH-SY5Y cells                                    | ↑/apoptosis                                                      | ↑/Akt3 ↑/CSK-33β/β-catenin                                          | [97]                                          |
| miR-26a           | ↓/PBMCs                                            | ↑/α-syn                                                          | ↑/DAPK1 [106]                                                      |                                               |
| miR-27a/27b       | ↑/midbrain                                          | ↑/mitochondrial fragmentation ↑/ROS                              | ↓/PARKIN                                                           | ↓/PINK1 [6]                                  |
| miR-29c           | ↑/serum [78]                                       |                                                                   |                                                                       |                                               |
| miR-29c-3p        | ↓/DA neuron                                        | ↓/autophagy                                                      | ↑/TET2                                                              |                                               |
| miR-29b           | ↓/serum [74,82]                                    |                                                                   |                                                                       |                                               |
| miR-34a-5p        | ↑/EVs [79]                                         | ↑/SH-SY5Y cells                                                  | ↑/ER stress                                                         | ↓/IRE1α [107]                                |
| miR-103           | ↓/MN9D cells ↓/C57BL/6 mice                       | ↑/LC3-II ↑/p62                                                   | ↑/CDK5R1/CDK5                                                      | [108]                                         |
| miR-105-5p        | ↑/serum [77]                                       |                                                                   |                                                                       |                                               |
| miR-107           | ↓/MN9D cells ↓/C57BL/6 mice                       | ↑/LC3-II ↑/p62                                                   | ↑/CDK5R1/CDK5                                                      | [108]                                         |
| miR-123-3P        | ↓/hippocampal tissue                               | ↑/apoptosis                                                      | ↑/Axin1 ↓/Wnt/β-catenin                                             | [109]                                         |
| miR-124           | ↓/brain                                            | ↑/cytokines ↑/apoptosis ↓/autophagy                               | ↑/MEKK3/NF-κB ↑/62/p38 ↑/Hedgehog [111]                             |                                               |
| miR-125b-5p       |                                                   |                                                                   |                                                                       |                                               |
| miR-128           | ↑/brain                                            | ↑/DA neuron                                                      | ↑/α-syn                                                             | ↓/TFEB [90]                                  |
| miR-132-3p        | ↓, ↑/serum [73–75]                                | ↑/apoptosis                                                      |                                                                       |                                               |
| miR-133a          | ↓/PC-12 cells                                      | ↑/apoptosis                                                      | ↑/RAC1 [112]                                                       |                                               |
| miR-133b          |                                                   |                                                                   | FAIM [105]                                                         |                                               |
| miR-137           | ↑/plasma                                           | ↑/ROS                                                           | ↑/OXR1                                                              | [113]                                         |
| miR-138-5p        | ↑/SH-SY5Y cells                                    | ↑/TNF-α ↑/IL-1β ↑/ROS                                           | ↑/SIRT1                                                             | [114]                                         |
| miR-144           | ↓/brain                                            | ↑/autophagy                                                      | ↑/mTOR                                                              | [115]                                         |
| miR-146a          | ↑/SH-SY5Y cells                                    | ↑/mitochondrial fragmentation ↑/ROS                              | ↑/β-amyloid precursor protein [89]                                  |                                               |
| miR-146-5p        | ↓/serum [73,74]                                    |                                                                   |                                                                       |                                               |
| miR-153           | ↓/brain                                            | ↑/α-syn                                                          | ↑/HO-1                                                              | [84]                                          |
| miR-155           | ↑/C57BL/6 mice                                     | ↑/α-syn ↑/INOS                                                   | ↑/MHCII                                                             | [80]                                          |
| miR-155-5p        | ↑/PBMCs [107]                                      | ↑/α-syn                                                          | ↑/INOS                                                              | [81]                                          |
| miR-181a          | ↓/serum                                            | ↑/apoptosis                                                      | ↑/p38MAPK/JNK                                                      | [116]                                         |
### Table 2. Cont.

| Species of miRNAs | Changes in miRNA Levels in PD’s Brain, CSF and Serum | Changes in miRNA Levels in Genetic Mouse Models and Cell Models for PD | Response of miRNA to PD “Triggers” In Vitro (Exposure Time if Relevant) | miRNA Target Genes (Experimentally Validated) |
|-------------------|-----------------------------------------------------|---------------------------------------------------------------------|------------------------------------------------------------------------|---------------------------------------------|
| miR-183           | ↑/brain                                             | ↑/substantia nigra neurons                                          | ↑/apoptosis                                                           | ↓/OSMR [117]                                |
| miR-185           | ↓                                                   |                                                                      | ↑/ROS                                                                  | ↑/PI3K/akt, ↓/IGFI1 [98]                    |
| miR-195           | ↑/serum                                             |                                                                      | ↑/neuroinflammation                                                   | ↑/ROCK1 [78, 118]                           |
| miR-200a-3p       | ↓/MPP-ADEXx                                         |                                                                      | ↑/apoptosis                                                           | ↑/MKK4 [119]                                |
| miR-204-5P        | ↑/brain                                             |                                                                      | ↑/α-syn [104]                                                         | ↑/DYRK1A [85]                               |
| miR-206           | ↓/apoptosis                                         |                                                                      |                                                                       | FAIM [105]                                  |
| miR-216           | ↑/SH-SY5Y                                           |                                                                      | ↑/TNF-α, ↑/IL-1β, ↑/ROS                                              | ↓/SIRT1 [84]                                |
| miR-217           | ↓/brain                                             | ↓/brain SN of PD rats                                               | ↑/apoptosis                                                           | ↑/ROCK1 [121]                               |
| miR-223           | ↓/brain [72]                                        | ↓/serum, ↓/saliva                                                   |                                                                       |                                            |
| miR-291           | ↓/ROCK2                                             |                                                                      |                                                                       |                                            |
| miR-326           | ↓/brain                                             | ↓/autophagy                                                         | ↑/XBPI [94, 95], ↑/MAPK/KLK7                                         |                                            |
| miR-331-5p        | ↓/CSF [103]                                         |                                                                      |                                                                       |                                            |
| miR-342-3p        | ↑/C57BL/6 mice                                      | ↑/apoptosis                                                         | ↓/PAK1                                                                |                                            |
| miR-380-3p        | ↑/N2a                                               | ↑/apoptosis                                                         | ↓/Wnt [123]                                                           |                                            |
| miR-486-5p        | ↑/colonic biopsies [76]                             |                                                                      |                                                                       |                                            |
| miR-599           | ↓/brain                                             |                                                                      |                                                                       | ↑/LERK2 [80]                                |
| hsa-miR-626       | ↓/CSF [100]                                         |                                                                      |                                                                       |                                            |
| hsa-miR-19b-3p    | ↑/CSF [124]                                         |                                                                      |                                                                       |                                            |

### 4.3. microRNA in Neuroinflammation of PD

Recent research has shown that miRNA can directly regulate the activation of microglia and affect neuroinflammation development in PD. Some miRNAs are specifically expressed in microglia (e.g., miR-125b-5p, miR-342-3p, and miR-99a) [125]. Postmortem analysis of patients with PD and healthy subjects showed that miRNAs were negatively correlated with cytokines. The downregulation of miR-218, miR-124, and miR-144 is related to PD through the activation of the NF-κB signaling pathway [126]. Our previous study showed that miR-124 can inhibit neuroinflammation during the development of PD by regulating the mitogen-activated protein kinase kinase kinase (MEKK3)/NF-κB signaling pathways. Overexpression of miR-124 or knockdown of MEKK3 could prevent neuronal death and apoptosis following microglial activation in the microglial culture supernatant transfer model or PD mouse model [8]. We also found that miR-124 suppressed the secretion of pro-inflammatory mediators by targeting 62/p38 expression and promoting autophagy in the inflammatory pathogenesis of PD [110]. Increased miR-124 expression can suppress neuroinflammation and autophagy in PD development by inhibiting the Hedgehog signaling pathway [111]. MiR-155 regulates alpha-synuclein-induced inflammatory responses in PD models. miR-155 likely lies upstream of the primary histocompatibility complex class II (MHC II) antigen presentation because knocking out miR-155 can prevent the induction...
of MHC II expression in PD [82]. The change in TNF-α expression precedes the change in IL-1β, IL-6, iNOS, and COX-2 expression, and the downregulation of miR-7116-5p in microglia MPP+ sensitizes TNF-α production to induce DA neuron damage in PD [127]. MiR-7 targets nod-like receptor protein three inflammasomes to modulate neuroinflammation and protect DA neurons against degeneration in the pathogenesis of PD [128]. CDC42, a candidate gene for PD involved in neuronal death, has been identified as a potential target for miRNAs 29a-3p and 103a-3p, while Rho-associated coil-containing protein kinase (ROCK)/CDC42-mediated microglial motility and glimpse formation leads to phagocytosis of degenerating DA neurons in vivo [129]. MiR-135b upregulates cell proliferation, apoptosis, and production of inflammatory cytokines such as TNF-α and IL-1β in MPP+-intoxicated SH-SY5Y cells by directly targeting glycogen synthase kinase-3β (GSK3β) [130]. Increased miR-129 levels prevent inflammation-induced neuronal and blood–spinal cord barrier (BCSB) damage by inhibiting high-mobility group box-1 (HMGB1) and TLR3-related cytokines, thereby preventing ischemia-reperfusion (IR) [131]. By targeting AKT3, miR-150 suppresses the release of pro-inflammatory cytokines (IL-1β, IL-6, and TNF-α) and inhibits the neuroinflammatory responses of cells treated with LPS [132,133]. miR-217/miR-138-5p downregulation evokes inhibition of ROS and TNF-α release, lactate dehydrogenase (LDH) activity, and cell apoptosis [134]. MiR-375 has been shown to be observably downregulated in PD [135]. Overexpression of miR-375 was verified to ameliorate abnormal behavior and the loss of dopaminergic neurons and abate oxidative stress and release of TNF-α, IL-6, and other neuroinflammation factors via inhibition of SP1, a transcriptional factor that lowers expression, indicating favorable neuronal survival [136]. Downregulation of miR-21 promotes the release of pro-inflammatory cytokines (IL-6, IL-1β, and TNF-α) and ROS production by negatively modulating the expression of Bcl-2 [137]. Additionally, miR-3473b modulates the secretion of TNF-α, IL-β, and other inflammatory factors by targeting TREM2/ULK1 expression to affect autophagy’s function in neuroinflammation in PD [138].

![microRNAs in PD pathogenesis](image)

**Figure 4.** miRNA representative signal pathways involved in Parkinson’s disease pathogenesis. Straight arrows indicate miRNAs regulate gene (protein) expression in PD pathogenesis. Two consecutive arrows mean that there may be other participants in the process.

In the past few years, the mechanism of miRNA and microglial activation has been further revealed, and these miRNAs also play a critical role in the pathogenesis of PD. For instance, inhibition of miR-155 modulates endotoxin tolerance by upregulating sup-
pressor of cytokine signaling-1 in microglia. Notably, the expression of miR-155 can be modified by levodopa treatment; in fact, a downregulation of miR-155 with the highest dosage is observed in patients with PD [81,139]. Moreover, knockdown of miR-146a can suppress the activation of microglia in mice, and analysis of miRNA expression shows that miR-146a-5p expression is downregulated in patients with PD compared to that in HCs [81,140]. Accordingly, miR-7 alleviates the secondary inflammatory response of microglia caused by cerebral hemorrhage by inhibiting toll-like receptor 4 (TLR4) expression, while facilitating the degradation of α-syn and its aggregates by promoting autophagy to protect against DA neuronal loss in vivo [141–143]. Moreover, microRNA-330 sponges could suppress LPS-induced polarization of microglia in a chronic neuroinflammatory model, prospectively by negatively modulating NF-κB activity and inflammatory cytokines such as iNOS by targeting SHIP1 in microglia [144]. MiR-let-7a expression was found to be decreased in a PD mouse model, and its overexpression negatively regulated α-Syn-induced BV-2 microglial cell activation and the release of pro-inflammatory factors by inhibiting STAT3 expression [145]. miR-155-5p reinforced the microglial activation and inflammatory factors release, enhanced oxidative stress and cell apoptosis, as well as alleviating the motivation of PD mice through targeting SOCS1 and Nrf2 [125]. Another anti-inflammatory component, Triptolide, was also verified to attenuate the inflammatory impairment via miR155-5p/SHIP1 pathway [146]. Interestingly, treatment of patients with PD with different medications (dopamine receptor agonists: pramipexole at a dosage of 1.5 mg/day or piribedil at a dosage of 150 mg/day, L-dopa at a dosage of 150–200 mg/day, and amantadine at a dosage of 300 mg/day) significantly increased the levels of miR-7, miR-9-5p, miR-9-3p, miR-129, and miR-132 [147]. Additionally, miR-19b may act as a potential biomarker for levodopa therapy by modulating ubiquitin-mediated proteolysis [148].

The miRNAs that have been shown to regulate downstream genes in PD inflammation are summarized in Table 3 and Figure 5.

**Table 3.** microRNAs in PD neuroinflammation.

| Species of miRNAs | Changes in miRNA Levels in PD’s Brain, CSF and Serum | Changes in miRNA Levels in Genetic Mouse Models and Cell Models for PD | Response of miRNA to PD “Triggers” In Vitro (Exposure Time if Relevant) | miRNA Target Genes (Experimentally Validated) |
|-------------------|------------------------------------------------------|-----------------------------------------------------------------|---------------------------------------------------------------------|---------------------------------------------|
| miR-7             | ↓/PD’s serum [128]                                   | ↓/MPTP/p-treated mice↓/A53T tg/tg mice [128]                      | ↓/IL-1β↓/α-syn aggregation [142]↓/autophagy [142]                   | ↓/NLRP3 [148]↓/TLR4 [141]                  |
| miR-let-7a        | ↓/C57BL/6 mice ↓/LPS-exposed BV2 cells              | ↓/microglia activation ↓/TNF-α, IL-6, IL-1β, and IL-12            | ↓/STAT3 [145]                                                      |                                            |
| miR-21            | ↑/MPP(+) treated MES23.5 cells [137]                | ↑/iNOS ↑/IL-1β, IL-6 and TNF-α ↑/apoptosis                      | ↑/Bcl-2                                                             |                                            |
| miR-29a-3p        |                                                      | ↑/microglial motility ↑/phagocytosis                              |                                                                    | ↑/ROCK/CDC42 [129]                        |
| miR-30a-5p        | ↓/microglial [149]                                  | ↓/TNF-α, IL-1β and IL-10                                        | ↓/Neurod 1 ↓/MAPK/ERK                                              |                                            |
| miR-93            | ↓/LPS-exposed BV2 cells [150]                       | ↓/microglial activation ↓/iNOS, IL-6 and TNF-α                   | ↓/STAT3                                                            |                                            |
| miR-99a           | ↑/C57BL6 mice microglial [125]                      |                                                                |                                                                    |                                            |
| miR-103a-3p       |                                                      | ↑/microglial motility ↑/phagocytosis                              |                                                                    | ↑/ROCK/CDC42 [129]                        |
| miR-181           | ↓/BV2 cells [34]                                    | ↓/iNOS, NO and ROS ↓/microglial motility                         |                                                                    | ↑/PKC-δ                                   |
Table 3. Cont.

| Species of miRNAs | Changes in miRNA Levels in PD's Brain, CSF and Serum | Changes in miRNA Levels in Genetic Mouse Models and Cell Models for PD | Response of miRNA to PD “Triggers” In Vitro (Exposure Time if Relevant) | miRNA Target Genes (Experimentally Validated) |
|-------------------|-----------------------------------------------------|-----------------------------------------------------------------|--------------------------------------------------------------------------------------------------------------------------------|-----------------------------------------------|
| miR-124           | ↓/PD’s brain [8]                                      | ↓/BV2 cells [8]                                                  | ↓/neuroinflammation [11]/neuronal death [11]/apoptosis [8] ↓/TNF-α, iNOS, and IL-1β [110] ↓/autophagy [110] ↓/MEKK3/NF-κB [8] ↓/p62/p-38 [129] ↓/Hedgehog [130] |
| miR-125b-5p       | ↑/C57BL6 mice microglial [125]                       |                                                                 |                                                                                                                                  |                                               |
| miR-128           | ↑/A9,A10 DA neurons [90,151]                         |                                                                 | ↑/α-syn aggregation                                                                | ↓/p38 ↓/TFEB                                      |
| miR-129-5p        | ↓/C57BL6 mice [152]                                  | ↓/inflammation↓/blood-spinal cord barrier (BCSB)                  | ↓/HMGB1 ↓/TLR3                                                                  |                                               |
| miR-133b          | ↓/SH-SY5Y cells [128]                                | ↑/TNF-α, IL-1β↓/pyroptosis                                       | ↑/GSK-3β ↓/FoxO1 [153] ↓/TXNIP, NLRP3, Caspase-1 [153] |                                               |
| miR-138-5p        | ↑/MPP(+) induced SH-SY5Y cells [134]                 | ↑/IL-1β and TNF-α                                               | ↓/SIRT1                                                                     |                                               |
| miR-144           | ↓/PD’s brain                                         |                                                                 |                                                                                                                                  | ↑/NF-κB [126]                                     |
| miR-146a          | ↑/PD’s PBMCs [81,140]                                | ↑/microglial activation                                         |                                                                                                                                  |                                               |
| miR-150           | ↓/PD’s serum                                         | ↓/BV2 cells [154]                                                | ↓/IL-1β, IL-6 and TNF-α [154,155] ↓/AKT3                                         |                                               |
| miR-155           | ↑/PD’s PBMCs [81]                                    | ↑/C57BL6 mice [82]                                               | ↑/iNOS [82] ↑/microglial activation ↑/MHCII ↓/SOCS1                              |                                               |
| miR-155-5p        | ↑/PD’s PBMCs [81]                                    | ↑/C57BL6 mice [124]                                             | ↑/microglial activation?/oxidative stress ↑/apoptosis ↑/TNF-α and IL-1β         | ↓/SOCS1 ↓/Nrf2                                     |
| miR-188-3p        | ↓/PD’s serum                                         | ↓/pyroptosis [156]                                               | ↓/autophagy                                                                  | ↓/CDK50 ↓/NLRP3                                    |
| miR-190           | ↓/LPS-induced BV2 cells [157]                        | ↓/iNOS, IL-6 and TGF-β↑/IL-10                                    | ↓/NLRP3                                                                    |                                               |
| miR-195           | ↓/LPS-induced BV2 cells [118]                        | ↓/IL-6 and TNF-α↑/IL-4 and IL-10                                 | ↓/ROCK1                                                                   |                                               |
| miR-217           | ↑/MPP(+) induced SH-SY5Y cells [134]                 | ↑/iNOS                                                          | ↓/SIRT1                                                                    |                                               |
| miR-218           | ↓/PD’s brain                                         |                                                                 |                                                                                                                                  | ↑/NF-κB [147]                                     |
| miR-221           | ↑/CCI-induced rat model [138]                        | ↑/TNF-α, IL-1β, and IL-6 ↓/apoptosis                             | ↓/SOCS1 ↑/NF-κB ↑/p38 MAPK ↓/PTEN                                             |                                               |
| miR-330           | ↓/LPS-induced BV2 cells [144]                        | ↓/microglial polarization ↓/iNOS                                 | ↓/NF-κB ↑/SHIP1 and Arg1                                                     |                                               |
| miR-342-3p        | ↑/C57BL6 mice microglial [131]                       |                                                                 |                                                                                                                                  |                                               |
| miR-375           | ↓/6-OHDA treated Wistar rats substantia nigra [136]  | ↑/TNF-α, IL-6 and IL-1β ↓/SOD and GSH-Px ↑/MDA                 | ↓/SP1                                                                       |                                               |
| miR-347b          | ↑/LPS treated BV2 cells [138] ↑/C57/BL6 mice        | ↑/microglial motility ↓/autophagy                                | ↑/TREM2/ULK1                                                                |                                               |
| miR-7116-5p       | ↓/C57BL6 mice microglia [127]                        | ↓/IL-1β, IL-6, TNF-α and iNOS                                   |                                                                                                                                  |                                               |
ceRNA has been widely associated with the pathogenesis of PD and neuroinflammation in PD. The IncRNA PLK2 has been found to facilitate α-syn aggregation-induced autophagy by sponging the miR-126/PLK2 signaling pathway [160]. Additionally, the IncRNA SNHG, considered a pivotal regulator in various cancers, is also associated with neurodegenerative diseases. SNHG1 promotes the aggregation of α-syn via the R-15b-5/SIAH1 axis [40]. Another signaling molecule, SNHG14, was verified to alleviate dopaminergic neuron injury and suppress α-syn aggregation via a sponge of miR-133b [161].

ceRNAs are crucial regulators of autophagy dysfunction in PD. As mentioned above, NEAT1 is attributable to autophagy in PD [162], and miR-34-5p/SYT1 has been demonstrated to serve as a sponge IncRNA NEAT1 and influence autophagy and apoptosis [163]. Moreover, the HOTAIR IncRNA could aggravate dopaminergic neuron autophagy by modulating the miR-221-3P/NPTX2, miR-874-5p/ATG10, and miR-126-5p/RAB3IP axis both in vitro and in vivo [164–166]. With miR-125-5p sponged, IncRNA BDNF-AS negative repression is likely to enhance cell proliferation as well as restrain autophagy and apoptosis both in vivo and in vitro [167].

Accumulating evidence indicates that ceRNAs are another inflammatory mediator network that activates inflammamasomes during PD pathogenesis and induces microgliosis. Boros et al. and Simchovitz et al. detected the expression level of NEAT1, and the outcome showed an elevated level of NEAT1 in the peripheral blood cells and substantia nigra of patients with PD [168,169]. NEAT1 also exhibited a negative regulatory effect on neuron viability, activating the inflammatory response and oxidative stress by decreasing the expression of miR-1277-5P and consequently improving ARHGAP26 presentation [170]. The exhaustion of IncRNA NEAT1 reduced the release of TNF-α, IL-1β, and other neuroinflammatory cytokines and increased cell viability by targeting miR-124-3p and modulating PDE4B [171]. Wang et al. confirmed that miR-519a-3p/SP1 is another pathway regulated by NEAT1 [172]. It was discovered that NEAT1 was increasingly expressed in PD mouse models targeting the miR-212-3p/AXIN1, miR-212-5p/RAB3IP, miR-124/KLF4, and miR-374c-5p axis to suppress viability and promote the release of IL-1β, IL-6, and other inflammation factors [173–176], similarly participating in neuroinflammation, NEAT1
serves as a stimulative role of α-syn-induced activation of the NLRP3 inflammasome by targeting miR-1301-3p/GJB1 [177]. In addition to numerous animal and cell experiments, bioinformatics analysis also verified the crucial role of NEAT1 in ceRNAs in PD [144]. As a sponge for miR942-5, the lncRNA SRY-box regulates oxidative stress, inflammation, and neuronal apoptosis by indirectly mediating NAIF1 [178]. Additionally, lncRNA NORAD acts as a sponge of miR-204-5p by holding SLC5A3, and NORAD overexpression causes cytotoxicity, inflammatory response, and oxidative stress [179,180]. LncRNA AL049437 is a ceRNA for miR-205-5p, upregulated both in vivo and in vitro in PD models, and has been shown to induce neuroinflammation and oxidative stress in the disease by modulating MAPK1 [181]. Additionally, through the downregulation of miR-101, lncRNA Mirt2 inhibits the secretion of inflammatory cytokines and oxidative stress by blocking the TNF-α-triggered NF-κB/p38MAPK pathway [182]. With HOTTIP sponging to miR-615-3p, HOTTIP downregulation alleviates microglial activation, pro-inflammatory cytokine secretion and neuron death by lowering the expression of FOXO1 [183]. By binding to the miR-425-5p/TRAFL axis, SNHG7 serves as a ceRNA to modulate inflammation and oxidative stress in cell and mouse models [184].

Abnormal apoptosis elicitation is involved in the pathogenesis of PD, and ceRNA networks have been linked to inappropriate apoptosis control, leading to dopamine neuron death. For instance, miR-51PA-3p can directly bind to NEAT, thereby inhibiting its expression, and its knockdown was verified to inhibit MPP(+) induced repression of cell viability [172]. LINC00943 was found to be upregulated in MPP(+) cells, and increased the secretion of pro-inflammatory cytokines (TNF-α, IL-1β, and IL-6), oxidative injury, and apoptosis by inhibiting the miR-15b-5p/RAB3IP [185], miR-7b-5p/CXCL12 [186], and miR-142-5p/KPNA4/NF-κB axis [187]. The Wnt/β-catenin signal pathway plays a vital role in neurorestoration [188], while overexpression of lncRNA H19 protects dopaminergic neurons from loss by activating the Wnt/β-catenin pathway by repressing miR-301b-3p dependent HPRT1 expression [189]; moreover, H19 has been reported to attenuate neuronal injury by targeting the miR-585-3p signaling pathway [190]. Neural stem cells (NSCs) are now an effective therapeutic method for PD; miR-204-5p was found to increase in the course of NSCs differentiating into both neuron and astrocyte cells, as well as the repression of lncRNA ADNCR and TCF3, suggesting that lncRNA ADNCR may act as a sponge for miR-204-5p to regulate NSC differentiation by regulating TCF3 expression [191] (Table 4) (Figure 6).
Table 4. Cont.

| Non-Coding RNA | Species of ncRNAs | Expression | Related Genes | Functional Role in PD | References |
|----------------|-------------------|------------|---------------|-----------------------|------------|
| SNHG7          | ↑                 | miR-425-5P/TRA5 | ↑/neuronal apoptosis ↑/TH-positive cell loss ↑/microglial activation ↑/oxidative stress ↑/neuroinflammation | [184]      |
| NEAT1          | ↑                 | miR-34-5p/SYT1 miR-51PA-3p | ↑/autophagy ↑/apoptosis ↓/cell proliferation | [162,163,172] |
| HOTAI          | ↑                 | miR-221-3P/NPTX2 miR-874-5p/ATG10 miR-126-5p/RAB3IP miR-326/ELAVL1 | ↑/autophagy ↑/apoptosis ↓/cell proliferation ↑/NLRP3 inflammasome activation | [164] |
| BDNF-AS        | ↑                 | miR-125b-5p | ↑/autophagy ↑/apoptosis ↓/cell proliferation | [167]      |
| NEAT1          | ↑                 | miR-1277-5P/ARHGAP26 miR-124-3p/PDE4B miR-519a-3p/SP1 miR-212-3p/AXIN1 miR-212-5p/RAB3IP miR-124/KLF4 miR-374c-5p miR-1301-3p/GJB1 | ↑/neuroinflammation (IL-6, TNF-α, IL-1β) ↓/neuron viability ↑/apoptosis ↑/NLRP3 inflammasome activation | [163, 170–174, 176] |
| SRY-box        | ↑                 | miR942-5/NAIF1 | ↑/apoptosis ↑/cleaved caspase-3 protein expression ↑/TNF-α, IL-1β, ROS and LDH | [178]      |
| NORAD          | ↓                 | miR-204-5p/SLC5A3 | ↓/cytotoxicity ↓/inflammatory response ↓/oxidative stress (ROS) | [179,180] |
| AL049437       | ↑                 | miR-205-5p/MAPK1 | ↑/cytotoxicity↑/inflammatory response ↑/oxidative stress (ROS) | [181]      |
| Mirt2          | ↓                 | miR-101/NF-kB/p38MAPK | ↓/inflammatory response (IL-6, TNF-α, IL-1β) ↓/oxidative stress (ROS) ↓/apoptosis | [182]      |
| HOTTIP         | ↑                 | miR-615-3p/FOXO1 | ↑/microglial activation, ↑/proinflammatory cytokine secretion (IL-1β, IL-6, IL-18, TNF-α, iNOS, COX2, NF-κB) ↑/apoptosis | [183]      |
| LINC00943      | ↑                 | miR-13b-5p/RAB3IP miR-7b-5p/CXCL12 miR-142-5p/KPNA4/NF-κB | ↑/TNF-α, IL-1β and IL-6 ↑/oxidative injury ↑/apoptosis | [185–187] |
| Non-Coding RNA | Species of ncRNAs | Expression | Related Genes | Functional Role in PD | References |
|---------------|-------------------|------------|---------------|-----------------------|------------|
| BACE1-AS      |                   | ↑          | miR-34b-5p/BACE | ↑/TNF-α, IL-1β and IL-6 ↑/oxidative injury ↑/apoptosis | [193] |
| H19           | miR-301b-3p/HPRT1/Wnt/β-catenin miR-585-3p | ↓          | ↓/neuron loss ↓/neuronal injury | [189,190] |
| UCA1          | miR-423-5p/KCTD20 | ↑          | ↑/cytotoxicity ↑/apoptosis | [194] |
| SOX21-AS1     | miR-7-5p/IR52     | ↑          | ↑/cell injury | [195] |
| MALAT1        | miR-135b-5p/GPNMB | ↑          | ↓/cell proliferation ↑/apoptosis | [196] |
| TUG1          | miR-152-3p/PTEN   | ↑          | ↑/cell apoptosis ↑/oxidative stress ↑/neuroinflammation | [197] |
| HAGLROS       | miR-100/ATG10 PI3K/Akt/Mtor | ↑          | ↑/cell apoptosis ↓/proliferation | [154] |
| MIAT          | miR-34-5p/SYT1    | ↓          | ↓/apoptosis | [198] |
| HOXA11-AS     | miR-124-3p/FSTL1  | ↑          | ↑/NLRP3 inflammasome activity ↑/microglial activation | [50] |
| Linc-p21      | miR-625/TRPM2     | ↑          | ↑/oxidative stress | [26,34] |
| ADNCR         | miR-204-5p/TCF3   | ↑          | ↑/microglial activation, ↑/apoptosis | [31] |
| T199678       | miR-101-3p        | ↓          | ↓/oxidative stress ↓/apoptosis | [35] |
| GAS5          | miR-223-3p/NLRP3  | ↑          | ↑/cell apoptosis, ↑/α-synuclein aggregation ↓/autophagy | [199] |
| circRNA       | circSNCA          | ↑          | miR-7          | ↑/cell apoptosis ↑/α-synuclein aggregation ↓/autophagy | [200] |
| circDLGAP4    | miR-134-5p/CREB   | ↓          | ↓/autophagy ↓/ mitochondrial dysfunction ↓/apoptosis | [201] |
| circSAMD4A    | miR-29c-3p/AMPK/mTOR | ↑          | ↑/autophagy ↑/apoptosis | [202] |
| circzip-2     | miR-60-3p/Daf-16  | ↓          | ↓/α-synuclein expression ↓/ROS | [203] |
| circSLC8A1    | miR-128/Ago2      | ↑          | ↑/oxidative stress | [204] |
| Circ_0070441  | miR-626/IRS2      | ↑          | ↑/cell apoptosis ↑/inflammation | [205] |
Circulating miRNA in the Pathogenesis Neuroinflammation of PD

4.5. Circulating miRNA in the Pathogenesis Neuroinflammation of PD

miRNAs are enriched in the brain tissue and play an essential role in the pathogenesis of Parkinson’s disease; therefore, they have been considered as potential diagnostic biomarkers. However, our capacity deficiency in accessing patients’ brain tissue from a specific region (such as the substantia nigra) is a major obstacle to the detection of miRNAs in PD. Therefore, the discovery of minimally invasive biomarkers is of great interest. Circulating cell-free miRNAs exist in the extracellular circulation, including plasma, serum, cerebrospinal fluid, saliva, urine, breast milk, and seminal plasma [205]. They are stable in severe environmental conditions and resistant to cellular RNase in circular systems owing to their existence in extracellular spaces [206,207]. Previous studies have proposed five different ways of miRNA transportation into extracellular fluid: bound with high-density lipoprotein complex particles in non-vesicle form, formed into complexes with multiple proteins (Ago2 and NPM1), packaged within exosomes, encapsulated within microvesicles (MVs), and accumulated in apoptotic bodies [208]. Exosomes have the potential to cross the blood–brain barrier via the membrane fusion process; therefore, miRNAs packaged within exosomes could also be considered as potential treatment targets [209–212]. Changing the expression profiles of miRNAs under pathogenetic and physiological states and their transportability through the brain–blood barrier have promoted the study of their potential application as biomarkers of Parkinson’s disease to diagnose at an early stage and identify new therapeutic targets (Table 5).

Emerging evidence has revealed that miR-34a-5p plays important roles in mammalian neurogenesis, synaptogenesis, and neural differentiation, and it has recently been regarded as a common dysregulated miRNA in different disorders of the CNS [213]. Grossi et al. reported that miR-34a-5p was significantly overexpressed in pure SEVs from the plasma of patients with PD compared to that in healthy controls. Additionally, pure SEVs miR-34a-5p levels were higher in patients with PD even at the initial stage of PD when the disease duration was less than 5 years. Its expression in pure SEVs revealed a good ability of this miRNA to distinguish patients with PD from control subjects, suggesting its potential use as a diagnostic marker at the molecular level [79].

Chen et al. developed a miRNA profiling strategy for circulating miRNAs isolated from the blood serum of 78 patients with PD and 78 normal controls, and seven of the
most differentially expressed miRNAs were selected and further assessed by qRT-PCR. The results showed that elevated miR-133b and miR-221-3p levels differentiated early-stage PD from controls [214]. An interesting study demonstrated that the expressions of miR-106a-5p, miR-103a-3p, and miR-29a-3p in the experimental group were upregulated after physical exercise and were associated with cognitive improvement in patients with PD, suggesting evidence for the efficacy of physical exercise in maintaining or alleviating PD development [215]. Using a similar approach, Oliveira et al. identified and validated the low expression of serum miR-146a, miR-335-3p, and miR-335-5p in iPD (n = 45) and LRRK2-PD (n = 20) compared to the control group (n = 20) [216]. Doxakis integrated the studies and conducted bioinformative analysis, and the results showed 81 differentially expressed miRNAs from patients with PD and healthy controls. Gene function and pathway analysis of the deregulated miRNAs revealed biological pathways related to PD pathogenesis, including the FoxO signaling pathway, TNF signaling pathway, and ErbB signaling pathway, and indicated that autophagy participated in PD pathogenesis [217].

Table 5. Circulating miRNA in the pathogenesis neuroinflammation of PD.

| Sample Source | Species | miRNAs Status in PD | Method | Pilot Study | References |
|---------------|---------|---------------------|--------|-------------|------------|
| serum         | human   | ↑/hsa-miR-7-5p, hsa-miR-22-3p, hsa-miR-136-3p, hsa-miR-139-5p, hsa-miR-330-5p, hsa-miR-433-3p, hsa-miR-495-3p | qRT-PCR | 99 iPD vs. 101 HC | [218] |
| human         | ↑/miR-96-5p | qRT-PCR | 51 PD vs. 52 HC | [219] |
| human         | ↓/hsa-miR-144-3p | NGS qRT-PCR | 61 PD vs. 58 HC | [220] |
| human         | ↓/hsa-miR-24-3p and hsa-miR-30c-5p | qRT-PCR | 38 PD vs. 20 HC | [221] |
| human         | ↑/miR-151a-5p, miR-24, mir-485-5p, mir-331-5p, and mir-214 | qRT-PCR | 209 PD vs. 60 HC | [222] |
| human         | ↓/miR-214, miR-221, and miR-141 | qRT-PCR | 20 PD vs. 15 HC | [223] |
| human         | ↓/hsa-mir-4745-5p | qRT-PCR | 12 PD vs. 12 HC | [225] |
| human         | ↓/hsa-mir-374a-5p | qRT-PCR | 68 PD vs. 50 HC | [226] |
| human         | ↑/miR-21-3p, miR-22-3p and miR-223-5p | qRT-PCR | 40 PD vs. 33 HC | [227] |
| human         | ↑/miR-34a-5p | qRT-PCR | 15 PD vs. 14 HC | [79] |
| human         | ↑/miR-133b and miR-221-3p | qRT-PCR | 151 PD vs. 138 HC | [214] |
| human         | ↓/miR-124 | qRT-PCR | 25PD vs. 21 HC | [228] |
| human         | ↑/hsa-miR-374a-5p, hsa-miR-374b-5p | qRT-PCR | 72 PD vs. 31 HC | [229] |
| human         | ↑/miR-106a-5p, miR-103a-3p, miR-29a-3p | qRT-PCR | 8PD (after exercise) vs. 8PD (before exercise) | [215] |
| Sample Source | Species | miRNAs Status in PD | Method | Pilot Study | References |
|---------------|---------|---------------------|--------|------------|------------|
| human         | ↓//miR-132-3p, miR-146-5p | qRT-PCR | 82 PD vs. 44 HC | [73] |
| human         | ↑//miR-27a-3p, miR-584-5p | NGS | 7 PD vs. 24 HC | [230] |
| human         | ↓//miR-146a, miR-335-3p, miR-335-5p | qRT-PCR | 20 iPDS vs. 20 HC | [220] |
| human         | ↓//miR-150 | qRT-PCR | 80 PD vs. 80 HC | [134] |
| human         | ↑//miR-330-5p, miR-433-3p, miR-495-3p | qRT-PCR | 108 PD vs. 92 HC | [231] |
| human         | ↓//miR-218, miR-124, miR-144 | qRT-PCR | 37 PD vs. 40 HC | [74] |
| human         | ↑//miR-132 | qRT-PCR | 269 PD vs. 222 HC | [75] |
| CSF human     | ↑//miR-151a-5p, miR-24, mir-485-5p, mir-331-5p, and mir-214 | qRT-PCR | 209 PD vs. 60 HC | [222] |
| human         | ↑//miR-7-5p, miR-331-5p, miR-145-5p | qRT-PCR | 10 PD vs. 10 HC | [103] |
| human         | ↓//hsa-miR-626 | qRT-PCR | 15 PD vs. 16 HC 20 PD vs. 27 PD HC | [100,232] |
| saliva human  | ↓//miR-29a-3p, miR-29c-3p | qRT-PCR | 5 PD vs. 5 HC | [233] |
| human         | ↓//miR-153, miR-223 | qRT-PCR | 83 PD vs. 77 HC | [72] |

5. circRNA

5.1. Introduction

circRNA was first discovered in viroids by Sanger in 1976 [234]. It is a type of ncRNA molecule with a closed-loop structure. There is no 5′-cap arrangement and a 3′-poly tail; therefore, it is not easily degraded by RNase [235]. It primarily exists in the cytoplasm and in exosomes [236]. circRNA is formed by reverse splicing of pre-mRNA, and its circularization process is regulated by RNA polymerase II (Pol II), cis-acting elements, trans-acting factors, and RNA-binding proteins [235]. According to their formation mechanism, circRNAs can be divided into three categories: single or multiple exons (circRNA), formed by the failure of debranching of the intron lasso (circRNAs), and both introns and exons (EIciRNAs) [237]. The degradation mechanism of circRNAs is still poorly understood, and it has been suggested that they may be degraded by small RNAs [238].

5.2. circRNA in the Pathogenesis of PD

As previously mentioned, mitochondrial dysfunction, oxidative stress, altered protein handling, and neuroinflammation are involved in the pathogenesis of PD. Some studies have shown that circRNAs participate in at least one of these pathological processes. Kong et al. used RNA sequencing and found that hsa_circ_0001451, hsa_circ_0001772, and hsa_circ_0036353 were downregulated in the peripheral blood RNAs of patients with PD, encoded for FBXW7, RBM33, and SIN3A [239]. Ravanidis et al. performed qRT-PCR of total RNA in patients with PD and healthy controls and found that Hsa_circ_0000497 was downregulated in the peripheral blood of patients with PD, which is encoded by the SLAIN motif family member-1 (SLAIN1) gene, microtubule-associated proteins, and is essential for axon elongation in neuronal development. Therefore, the deregulation of hsa_circ_0000497 deregulates offline cytoskeletal dynamics, which is expected to diminish intracellular
signaling pathways and has been regarded as a critical factor in the pathogenesis of multiple neurodegenerative diseases, including PD [240].

5.3. circRNA in Neuroinflammation of PD

The relationship between circRNAs and inflammation is now gaining recognition, and some studies have revealed that circRNAs participate in diabetes mellitus [241], atherosclerosis [242], osteoarthritis [243], and spinal cord injury [244], all of which are associated with immunoinflammatory effects. However, circRNA profiling and the regulatory mechanisms of neuroinflammation in PD remain unclear.

5.4. ceRNA in the Pathogenesis and Neuroinflammation of PD

circRNAs can relieve the inhibitory effect of miRNA on mRNA because they are rich in miRNA binding sites. In addition, circRNA does not contain 3' and 5' free ends, so it is not easily degraded by exonucleases, enhancing its function as a miRNA sponge [245]. circRNAs are known to act as miRNA sponges, circSNCA was confirmed to be another miR-7 repressor, and it was found to be downregulated in a pramipexole-worked PD cell model as well as an inhibitor of α-syn deposition, while miR-7 was upregulated [199]. Besides being associated with α-syn aggregation, circRNAs are also attributable to autophagy in PD. circDLGAP4 acts as a sponge for miR-134-5p and plays a role in suppressing its functional activity of miR-134-5p. circDLGAP4 was reported to be downregulated in an MPTP-induced PD animal model, which could promote autophagy; inhibit mitochondrial dysfunction, and suppress apoptosis by modulating the activation of CREB by regulating miR-134-5p [200]. Similarly, miR-29c-3p, which targets and inhibits the expression of circSAMD4A, is involved in apoptosis and autophagy of dopaminergic neurons by regulating the AMPK/mTOR cascade [201]. Additionally, in the worm PD model, cirzip-2 was found to target miR-60-3p, which contains M60.4, igeg-2, got-2.2, K07H8.2, asns-2, pkg-2, ZK470.2, and idhgl-1 genes, which were found to be downregulated in the PD model [202]. Additionally, circSLC8A1 was verified to correlate with oxidative stress in Parkinsonism via binding to miR-128, regulating the microRNA effector protein Ago2 in the PD cell model [203]. Simultaneously, circ_0070441 can directly bind to miR-626, thereby indirectly regulating IRS2 expression, and its upregulation was verified to aggregate MPP(+) induced neurotoxicity in a PD cell model [204]. However, there is still a controversial issue about whether circRNAs can serve as miRNA sponges because some studies have revealed that most circRNAs do not have the function of sponging miRNAs [210] (Figure 6).

6. ncRNAs in Treatment of Parkinson’s Disease

ncRNA therapeutics comprise various groups of oligonucleotide-based drugs such as antisense oligonucleotides, small interfering RNAs (siRNAs), short hairpin RNAs (shRNAs) and clustered regularly interspaced short palindromic repeats (CRISPR/Cas) that can be designed to selectively interact with drug targets. However, as a result of the blood–brain barrier hindering medication delivery to the CNS, the drug delivery system is key to the envisioned drug role for ncRNAs. The drug delivery system consists of exogenous vectors (lentiviral vectors, adenoviral vectors, nanomedicines, liposomes, and lipid NPs) and endogenous vectors (exosomes). Owing to the disadvantages of toxicity and immunogenicity associated with viral vectors, major attention has been focused on the development of non-viral vectors, such as polymeric NPs, which may result in a safer and less toxic gene delivery method [245–251].

As drug carriers, exosomes have the advantages of optimized biocompatibility, blood–brain barrier penetrability, metabolic stability, and target specificity. Exosomes have been successfully loaded with catalase, dopamine, and small interfering RNA for PD treatment and have shown significant therapeutic effects. In 2014, Cooper et al. found that siRNA-loaded exosomes could significantly decrease the expression levels of α-syn mRNA and protein compared with that seen in healthy controls [251]. In 2015, Haney et al. delivered exosomes via nasal injection into a PD mouse model and demonstrated specific neuro-
protective effects. Recently, Kojima et al. reported that catalase mRNA-loaded exosomes effectively attenuated neurotoxicity and neuroinflammation in PD mice [252,253]. Therefore, it is worthwhile to develop a drug delivery system for exosomes for the treatment of PD.

Nanomedicine has also been studied for controlled delivery of genes to the brain. One particularly interesting example of the development of nanomedicines for microRNA delivery involves the use of polymeric nanoparticles for miR-124. It has been demonstrated that stereotactic injection into the right lateral ventricle of miR-124-loaded NPs attenuates neurogenesis in the subventricular zone, promoting migration and integration of mature neurons into the lesioned striatum of 6-OHDA–treated mice and improving motor symptoms [254].

7. Conclusions

In conclusion, this manuscript identifies and describes the multiform ncRNAs, including miRNAs, IncRNAs, and circRNAs, and their regulatory mechanisms participating in the pathogenesis of PD. Increasing evidence indicates that ncRNAs play a pivotal role in neuroinflammation and neurodegeneration in the CNS. However, more extensive ncRNA profiling data and experiments are required to ultimately invert transcriptional analysis into clinical treatment and diagnosis. Moreover, further research is needed to fully understand the intricate and unsuspected correlation between ncRNAs, proteins, and cellular physiology and pathology in PD. Recent studies have paid more attention to miRNAs and IncRNAs; the understanding of circRNAs is supposed to be deeply studied, especially neuroinflammation in PD, given the new technologies, such as second-generation sequencing. At the same time, it is essential to further clarify the spatial and temporal distribution of ncRNAs in PD. Silico and systematic analyzes must be performed to recognize the complicated network between ncRNAs and proteins in the pathogenesis of PD. Since pharmacotherapy, such as L-dopa and peripheral dopa decarboxylase inhibitors, can relieve motor symptoms but cannot restrain the development of PD, ncRNA-related treatment may become a potential and novel therapy in the development of PD on account of this evidence, such as cell replacement therapy and molecular targeting treatment. The ncRNA miR-204-5p increases during the differentiation of NSCs into both neurons and astrocytes. Another study showed that astrocytes can be induced to form dopamine neurons via NEUROD1, ASCL1, and LMX1A [143]. In sum, identifying ncRNAs involved in PD progression may lead to more effective diagnosis and treatment.

Author Contributions: L.Y. and H.Z. performed the majority of the literature search and predominantly contributed to the writing of the article. S.K., Z.Z. and G.L. assisted with the literature search. All authors have read and agreed to the published version of the manuscript.

Funding: This study was supported by the National Natural Science Foundation of China (82060249), Key project of National Natural Science Foundation of Jiangxi Province (20202ACBL206005), General project of Natural Science Foundation of Jiangxi Province (20192BAB205042), General project of Natural Science Foundation of Jiangxi Province (20202BABL206098), and the major academic and technical leaders training plan of Jiangxi Province-Youth Training Program (2020BCJ23019).

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Data sharing not applicable.

Acknowledgments: Not applicable.

Conflicts of Interest: The authors declare no conflict of interest.
References

1. Morris, K.V.; Mattick, J.S. The rise of regulatory RNA. Nat. Rev. Genet. 2014, 15, 423–437. [CrossRef] [PubMed]

2. Gupta, R.A.; Shah, N.; Wang, K.C.; Kim, J.; Horlings, H.M.; Wong, D.J.; Tsai, M.C.; Hung, T.; Argani, P.; Rinn, J.L.; et al. Long non-coding RNA HOTAIR reprograms chromatin state to promote cancer metastasis. Nature 2010, 464, 1071–1076. [CrossRef] [PubMed]

3. Cech, T.R.; Steitz, J.A. The noncoding RNA revolution-trashing old rules to forge new ones. Cell 2014, 157, 77–94. [CrossRef] [PubMed]

4. Zhao, G.; Su, Z.; Song, D.; Mao, Y.; Mao, X. The long non-coding RNA MALAT1 regulates the lipopolysaccharide-induced inflammatory response through its interaction with NF-κB. FEBS Lett. 2016, 590, 2884–2895. [CrossRef]

5. Niu, M.; Xu, R.; Wang, J.; Hou, B.; Xie, A. MiR-133b ameliorates axon degeneration induced by MPP(+) via targeting RhoA. Neuroscience 2016, 325, 39–49. [CrossRef]

6. Kim, J.; Fiesel, F.C.; Belmonte, K.C.; Hudec, R.; Wang, W.X.; Kim, C.; Nelson, P.T.; Springer, W.; Kim, J. MiR-27a and miR-27b regulate autophagic clearance of damaged mitochondria by targeting PTEN-induced putative kinase 1 (PINK1). Mol. Neurodegener. 2016, 11, 55. [CrossRef]

7. Wu, Y.Y.; Kuo, H.C. Functional roles and networks of non-coding RNAs in the pathogenesis of neurodegenerative diseases. J. Biomed. Sci. 2020, 27, 49. [CrossRef]

8. Yao, L.; Ye, Y.; Mao, H.; Lu, F.; He, X.; Lu, G.; Zhang, S. microRNA-124 regulates the expression of MEKK3 in the inflammatory pathogenesis of Parkinson’s disease. J. Neuroinflammm. 2018, 15, 13. [CrossRef]

9. Sundaram, J.R.; Poore, C.P.; Sulaimee, N.H.B.; Pareek, T.; Cheong, W.F.; Wenk, M.R.; Pant, H.C.; Frautschy, S.A.; Low, C.M.; Kesavapany, S. Curcumin Ameliorates Neuroinflammation, Neurodegeneration, and Memory Deficits in p25 Transgenic Mouse Model that Bears Hallmarks of Alzheimer’s Disease. J. Alzheimer’s Dis. JAD 2017, 60, 1429–1442. [CrossRef]

10. Amin, F.U.; Shah, S.A.; Kim, M.O. Glycine inhibits ethanol-induced oxidative stress, neuroinflammation and apoptotic neurodegeneration in postnatal rat brain. Neurochem. Int. 2016, 96, 1–12. [CrossRef]

11. Shah, S.A.; Amin, F.U.; Khan, M.; Abid, M.N.; Rehman, S.U.; Kim, T.H.; Kim, M.O.; Kim, M.W.; Kim, M.O. Anthocyanins abrogate glutamate-induced AMPK activation, oxidative stress, neuroinflammation, and neurodegeneration in postnatal rat brain. J. Neuroinflamm. 2016, 13, 286. [CrossRef] [PubMed]

12. Ransohoff, R.M. How neuroinflammation contributes to neurodegeneration. Science 2016, 353, 777–783. [CrossRef] [PubMed]

13. Ikeda-Matsuo, Y.; Miyata, H.; Mizoguchi, T.; Ohama, E.; Naito, Y.; Uematsu, S.; Akira, S.; Sasaki, Y.; Tanabe, M. Microsomal prostaglandin E synthase-1 is a critical factor in dopaminergic neurodegeneration in Parkinson’s disease. Neurobiol. Dis. 2019, 124, 89–92. [CrossRef]

14. Zhang, Y.; Feng, S.; Nie, K.; Li, Y.; Gao, Y.; Gan, R.; Wang, L.; Li, B.; Sun, X.; Wang, L.; et al. TREM2 regulates microglial phenotypes in the neuroinflammation of Parkinson’s disease. J. Neuroinflammm. 2018, 15, 13. [CrossRef]

15. Yu, Q.; Huang, Q.; Du, X.; Xu, S.; Li, M.; Ma, S. Early activation of Egr-1 promotes neuroinflammation and dopaminergic neurodegeneration in an experimental model of Parkinson’s disease. Exp. Neurol. 2018, 302, 145–154. [CrossRef] [PubMed]

16. Pal, R.; Tiwari, P.C.; Nath, R.; Pant, K.K. Role of neuroinflammation and latent transcription factors in pathogenesis of Parkinson’s disease. Neuronal Res. 2016, 38, 1111–1122. [CrossRef]

17. McFarland, A.J.; Davey, A.K.; McDermott, C.M.; Grant, G.D.; Lewohl, J; Anoopkumar-Dukie, S. Differences in statin associated neuroprotection corresponds with either decreased production of IL-1beta or TNF-alpha in an in vitro model of neuroinflammation-induced neurodegeneration. Toxicol. Appl. Pharmacol. 2018, 344, 56–73. [CrossRef]

18. Qin, H.; Buckley, J.A.; Li, X.; Liu, Y.; Fox, T.H., 3rd; Meares, G.P.; Yu, H.; Yan, Z.; Harms, A.S.; Li, Y.; et al. Inhibition of the JAK/STAT Pathway Protects Against alpha-Synuclein-Induced Neuroinflammation and Dopaminergic Neurodegeneration. J. Neurosci. Off. J. Soc. Neurosci. 2016, 36, 5144–5159. [CrossRef]

19. Johnson, J.M.; Edwards, S.; Shoemaker, D.; Schadt, E.E. Dark matter in the genome: Evidence of widespread transcription detected by microarray tiling experiments. Trends Genet. 2005, 21, 93–102. [CrossRef]

20. Pennisi, E. Shining a light on the genome’s ‘dark matter’. Science 2010, 330, 1614. [CrossRef]

21. Lin, D.; Liang, Y.; Jing, X.; Chen, Y.; Lei, M.; Zeng, Z.; Zhou, T.; Wu, X.; Peng, S.; Zheng, D.; et al. Microarray analysis of an long noncoding RNA Malat1-promoted neurodegeneration in Parkinson’s disease. Brain Res. 2018, 1678, 384–396. [CrossRef]

22. Cao, B.; Wang, T.; Qu, Q.; Kang, T.; Yang, Q. Long Noncoding RNA SNHG1 Promotes Neuroinflammation in Parkinson’s Disease via Regulating miR-7/NLRP3 Pathway. Neuroscience 2018, 388, 118–127. [CrossRef] [PubMed]

23. Fan, Y.; Li, J.; Yang, Q.; Gong, C.; Gao, H.; Mao, Z.; Yuan, X.; Zhu, S.; Xue, Z. Dysregulated Long Non-coding RNAs in Parkinson’s Disease Contribute to the Apoptosis of Human Neuroblastoma Cells. Front. Neurosci. 2019, 13, 1320. [CrossRef] [PubMed]

24. Greenamyre, J.T.; Betarbet, R.; Sherr, T.B. The rotenone model of Parkinson’s disease: Genes, environment and mitochondria. Parkinsonism Relat. Disord. 2003, 9 (Suppl. 2), S59–S64. [CrossRef]

25. Peng, W.X.; Koirala, P.; Mo, Y.Y. LncRNA-mediated regulation of cell signaling in cancer. Oncogene 2017, 36, 5661–5667. [CrossRef]

26. Kraus, T.F.; Haiden, M.; Spanner, J.; Steinmaurer, M.; Dietinger, V.; Kretzschmar, H.A. Altered Long Noncoding RNA Expression Precedes the Course of Parkinson’s Disease—a Preliminary Report. Mol. Neurobiol. 2017, 54, 2869–2877. [CrossRef]

27. Chi, L.M.; Wang, L.P.; Jiao, D. Identification of Differentially Expressed Genes and Long Noncoding RNAs Associated with Parkinson’s Disease. Parkinsonism Dis. 2019, 2019, 6078251. [CrossRef]
Pharmaceuticals 2022, 15, 811
28. Márki, S.; Göblös, Á.; Szlávicz, E.; Török, N.; Balicza, P.; Bereznai, B.; Takáts, A.; Engelhardt, J.; Klivényi, P.; Vécesi, L.; et al. The rs13388259 Intergenic Polymorphism in the Genomic Context of the BCYRN1 Gene Is Associated with Parkinson’s Disease in the Hungarian Population. Parkinsons Dis. 2018, 2018, 935198.

29. Liu, Y.; Lu, Z. Long non-coding RNA NEAT1 mediates the toxic of Parkinson’s disease induced by MPTP/MPP+ via regulation of gene expression. Clin. Exp. Pharmacol. Physiol. 2018, 45, 941–948. [CrossRef]

30. Zou, J.; Guo, Y.; Wei, L.; Yu, F.; Yu, B.; Xu, A. Long Noncoding RNA POU3F3 and α-Synuclein in Plasma LICAM Exosomes Combined with β-Glucocerebrosidase Activity: Potential Predictors of Parkinson’s Disease. Neurotherapeutics 2020, 17, 1104–1119. [CrossRef]

31. Bu, L.L.; Xie, Y.Y.; Lin, D.Y.; Chen, Y.; Jing, X.N.; Liang, Y.R.; Peng, S.D.; Huang, K.X.; Tao, E.O. LncRNA-Ti199678 Mitigates α-Synuclein-Induced Dopaminergic Neuron Injury via miR-101-3p. Front. Aging Neurosci. 2020, 12, 599246. [CrossRef] [PubMed]

32. Huang, H.; Zheng, S.; Lu, M. Downregulation of IncRNA MEG3 is involved in Parkinson’s disease. Metab. Brain Dis. 2021, 36, 2323–2328. [CrossRef] [PubMed]

33. Quan, Y.; Wang, J.; Wang, S.; Zhao, J. Association of the Plasma Long Non-coding RNA MEG3 With Parkinson’s Disease. Metab. Brain Dis. 2021, 36, 2317–2322. [CrossRef] [PubMed]

34. Ye, Y.; He, X.; Lu, F.; Mao, H.; Zhu, Z.; Yao, L.; Luo, W.; Sun, X.; Wang, B.; Qian, C.; et al. A lincRNA-p21/miR-181 family feedback loop regulates microglial activation during systemic LPS- and MPTP-induced neuroinflammation. Cell Death Dis. 2018, 9, 803. [CrossRef] [PubMed]

35. Xu, W.; Zhang, L.; Geng, Y.; Liu, Y.; Zhang, N. Long noncoding RNA GAS5 promotes microglial inflammatory response in Parkinson’s disease by regulating NLRP3 pathway through spiong miR-223-3p. Int. Immunopharmacol. 2020, 85, 106614. [CrossRef] [PubMed]

36. Wang, Q.; Han, C.L.; Wang, K.L.; Sui, Y.P.; Li, Z.B.; Chen, N.; Fan, S.Y.; Shimabukuro, M.; Wang, F.; Meng, F.G. Integrated analysis of exosomal IncRNA and mRNA expression profiles reveals the involvement of Inc-MKRN2-42 in the pathogenesis of Parkinson’s disease. CNS Neurosci. Ther. 2020, 26, 527–537. [CrossRef]

37. Simchovitz, A.; Hanan, M.; Yayon, N.; Lee, S.; Bennett, E.R.; Greenberg, D.S.; Kadener, S.; Soreq, H. A lncRNA survey finds increases in neuroprotective LINC-PINT in Parkinson’s disease substantia nigra. Aging Cell 2020, 19, e13115. [CrossRef]

38. Wang, S.; Ke, S.; Wu, Y.; Zhang, D.; Liu, B.; He, Y.H.; Liu, W.; Mu, H.; Song, X. Functional Network of the Long Non-coding RNA miR-181a-5p/CXCL12 axis. Oncotarget 2018, 9, 212–221. [CrossRef] [PubMed]

39. Lu, M.; Sun, W.L.; Shen, J.; Wei, M.; Chen, B.; Qi, Y.J.; Xu, C.S. LncRNA-UCA1 promotes PD development by upregulating SNCA. Eur. Rev. Med. Pharm. Sci. 2018, 22, 7908–7915. [CrossRef] [PubMed]

40. Chen, Y.; Lian, Y.J.; Ma, Y.Q.; Wu, C.J.; Zheng, Y.K.; Xie, N.C. LncRNA SNHG1 promotes α-synuclein aggregation and toxicity by targeting miR-15b-5p to activate SIAH1 in human neuroblastoma SH-SY5Y cells. Neurotoxicology 2018, 68, 212–221. [CrossRef] [PubMed]

41. Yang, X.; Zhang, Y.; Chen, Y.; He, X.; Qian, Y.; Xu, S.; Gao, C.; Mo, C.; Chen, S.; Xiao, Q. LncRNA HOXA-AS2 regulates microglial polarization via recruitment of PRC2 and epigenetic modification of PGC-1α expression. J. Neuroinflamm. 2021, 18, 197. [CrossRef] [PubMed]

42. Cai, L.J.; Tu, L.; Huang, X.M.; Huang, J.; Qiu, N.; Xie, G.H.; Liao, J.X.; Du, W.; Zhang, Y.Y.; Tian, J.Y. LncRNA MALAT1 facilitates inflammasome activation via epigenetic suppression of Nrf2 in Parkinson’s disease. Mol. Brain 2020, 13, 130. [CrossRef] [PubMed]

43. Wang, S.; Zhang, X.; Guo, Y.; Rong, H.; Liu, T. The long noncoding RNA HOTAIR promotes Parkinson’s disease by upregulating LRKK2 expression. Oncotarget 2017, 8, 24449–24456. [CrossRef] [PubMed]

44. Wang, H.; Wang, X.; Zhang, Y.; Zhao, J. LncRNA SNHG1 promotes neuronal injury in Parkinson’s disease cell model by regulating miR-181a-5p/CXCL12 axis. J. Mol. Histol. 2021, 52, 153–163. [CrossRef] [PubMed]

45. Xiao, X.; Tan, Z.; Jia, M.; Zhou, X.; Wu, K.; Ding, Y.; Li, W. Long Noncoding RNA SNHG1 Knockdown Ameliorates Apoptosis, Oxidative Stress and Inflammation in Models of Parkinson’s Disease by Inhibiting the miR-125b-5p/MAPK1 Axis. Neuropsychiatr. Dis. Treat 2021, 17, 1153–1163. [CrossRef] [PubMed]

46. Wang, H.; Zhang, M.; Wei, T.; Zhou, J.; Zhang, Y.; Guo, D. Long non-coding RNA SNHG1 mediates neuronal damage in Parkinson’s disease model cells by regulating miR-216a-3p/Bcl-2-associated X protein. Amn. Transl. Med. 2021, 9, 851. [CrossRef]

47. Zhao, J.; Gong, L.; Chen, Y.; Wu, C. SNHG1 promotes MPP+-induced cytotoxicity by regulating PTEN/AKT/mTOR signaling pathway in SH-SY5Y cells via spiong miR-153-3p. Biol. Res. 2020, 53, 1. [CrossRef]

48. Xie, N.; Qi, J.; Li, S.; Deng, J.; Chen, Y.; Lian, Y. Upregulated IncRNA small nucleolar RNA host gene 1 promotes 1-methyl-4-phenylpyridinium ion-induced cytotoxicity and reactive oxygen species production through miR-15b-5p/GSK3β axis in human dopaminergic SH-SY5Y cells. J. Cell Biochem. 2019, 120, 5790–5801. [CrossRef]

49. Qian, C.; Ye, Y.; Mao, H.; Yao, L.; Sun, X.; Wang, B.; Zhang, H.; Xie, L.; Zhang, H.; Zhang, Y.; et al. Downregulated IncRNA-SNHG1 enhances autophagy and prevents cell death through the miR-221/222 /p27/mTOR pathway in Parkinson’s disease. Exp. Cell Res. 2019, 384, 111614. [CrossRef]

50. Cao, H.; Han, X.; Jia, Y.; Zhang, B. Inhibition of long non-coding RNA HOXA11-AS against neuroinflammation in Parkinson’s disease model via targeting miR-124-3p mediated FSTL1/NF-κB axis. Aging (Albany NY) 2021, 13, 11455–11469. [CrossRef]

51. Ma, X.; Wang, Y.; Yin, H.; Hua, L.; Zhang, X.; Xiao, J.; Yuan, Q.; Wang, S.; Liu, Y.; Zhang, S.; et al. Down-regulated long non-coding RNA RMST ameliorates dopaminergic neuron damage in Parkinson’s disease rats via regulation of TLR/NF-κB signaling pathway. Brain Res. Bull. 2021, 174, 22–30. [CrossRef] [PubMed]
52. Ding, X.M.; Zhao, L.J.; Qiao, H.Y.; Wu, S.L.; Wang, X.H. Long non-coding RNA-p21 regulates MPP(+) -induced neuronal injury by targeting miR-625 and derepressing TRPM2 in SH-SYSY cells. *Chem. Biol. Interact.* 2019, 307, 73–81. [CrossRef] [PubMed]

53. Li, Y.; Liu, J.J.; Zhou, J.H.; Chen, R.; Cen, C.Q. LncRNA HULC induces the progression of osteosarcoma by regulating the miR-372-3p/HMGBl signalling axis. *Mol. Med.* 2020, 26, 26. [CrossRef] [PubMed]

54. Li, W.; Zheng, Z.; Chen, H.; Cai, Y.; Xie, W. Knockdown of long non-coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway. *Oncol. Lett.* 2018, 15, 7855–7863. [CrossRef] [PubMed]

55. Kim, I.S.; Koppula, S.; Park, S.Y.; Choi, D.K. Analysis of Epidermal Growth Factor Receptor Related Gene Expression Changes in a Cellular and Animal Model of Parkinson’s Disease. *Int. J. Mol. Sci.* 2017, 18, 430. [CrossRef] [PubMed]

56. Honarrad Tamizkar, K.; Gori, P.; Gholipour, M.; Hussien, B.M.; Mazdeh, M.; Esami, S.; Taheri, M.; Ghafouri-Fard, S. Parkinson’s Disease is Associated With Dysregulation of Circulatory Levels of lncRNAs. *Front. Immunol.* 2021, 12, 763323. [CrossRef]

57. Singh, S.S.; Rai, S.N.; Birla, H.; Zahra, W.; Rathore, A.S.; Singh, J.P. NF-κB-Mediated Neuroinflammation in Parkinson’s Disease and Potential Therapeutic Effect of Polyphenols. *Neurotox Res.* 2020, 37, 491–507. [CrossRef]

58. Hunot, S.; Brugg, B.; Ricard, D.; Michel, P.P.; Muriel, M.P.; Ruberg, M.; Faucheux, B.A.; Agid, Y.; Hirsch, E.C. Nuclear translocation of NF-κBp1 is increased in dopaminergic neurons of patients with parkinson disease. *Proc. Natl. Acad. Sci. USA* 1997, 94, 7531–7536. [CrossRef]

59. Ghafouri-Fard, S.; Gholipour, M.; Abak, A.; Mazdeh, M.; Taheri, M.; Sayad, A. Expression Analysis of NF-κB-Related IncRNAs in Parkinson’s Disease. *Front. Immunol.* 2021, 12, 755246. [CrossRef]

60. Bartel, D.P. microRNAs: Genomics, biogenesis, mechanism, and function. *Cell* 2004, 116, 281–297. [CrossRef]

61. Bartel, D.P. Metazoan microRNAs. *Cell* 2005, 121, 29–54. [CrossRef] [PubMed]

62. Alberti, C.; Manzenreither, R.A.; Sowemimo, I.; Burkard, T.R.; Wang, J.; Mahofsky, K.; Ameres, S.L.; Cochella, L. Cell-type specific sequencing of microRNAs from complex animal tissues. *Nat. Methods* 2015, 18, 283–289. [CrossRef] [PubMed]

63. Hosseini, M.; Khatamianfar, S.; Hassanian, S.M.; Nedaeinia, R.; Maftouh, M.; Ghayour-Mobarhan, M.; ShahidSales, S.; Avan, A. Exosome-Encapsulated microRNAs as Potential Circulating Biomarkers in Colon Cancer. *Curr. Pharm. Des.* 2017, 23, 1705–1709. [CrossRef] [PubMed]

64. O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of microRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front. Endocrinol.* 2018, 9, 402. [CrossRef]

65. Khee, S.G.; Yusof, Y.A.; Makpol, S. Expression of senescence-associated microRNAs and target genes in cellular aging and modulation by tocotrienol-rich fraction. *Oxid. Med. Cell Longev.* 2014, 2014, 725929. [CrossRef]

66. De Gregorio, R.; Pulcrano, S.; De Sanctis, C.; Volpicelli, F.; Guatteo, E.; von Oerthel, L.; Latagliata, E.C.; Esposito, R.; Piscitelli, R.M.; Perrone-Capano, C.; et al. MiR-34b/c Regulates Wnt1 and Enhances Mesencephalic Dopaminergic Neuron Differentiation. *Oxid. Med. Cell Longev.* 2018, 15, 491–507. [CrossRef]

67. Li, W.; Zheng, Z.; Chen, H.; Cai, Y.; Xie, W. Knockdown of long non-coding RNA PVT1 induces apoptosis and cell cycle arrest in clear cell renal cell carcinoma through the epidermal growth factor receptor pathway. *Oncol. Lett.* 2018, 15, 7855–7863. [CrossRef] [PubMed]

68. Ivey, K.N.; Srivastava, D. microRNAs as regulators of differentiation and cell fate decisions. *Cell Stem Cell* 2010, 7, 36–41. [CrossRef]

69. O’Brien, J.; Hayder, H.; Zayed, Y.; Peng, C. Overview of microRNA Biogenesis, Mechanisms of Actions, and Circulation. *Front. Endocrinol.* 2018, 9, 402. [CrossRef]

70. Khee, S.G.; Yusof, Y.A.; Makpol, S. Expression of senescence-associated microRNAs and target genes in cellular aging and modulation by tocotrienol-rich fraction. *Oxid. Med. Cell Longev.* 2014, 2014, 725929. [CrossRef] [PubMed]

71. Han, L.; Tang, Y.; Bai, X.; Liang, X.; Fan, Y.; Shen, Y.; Huang, F.; Wang, J. Association of the serum microRNA-29 family with cognitive impairment in Parkinson’s disease. *Aging (Albany NY)* 2020, 12, 13518–13528. [CrossRef]

72. Grasso, M.; Piscopo, P.; Talarico, G.; Ricci, L.; Crestini, A.; Tosto, G.; Gasparini, M.; Bruno, G.; Denti, M.A.; Confalonieri, A. Plasma microRNA profiling distinguishes patients with frontotemporal dementia from healthy subjects. *Neurobiol. Aging* 2019, 84, 240.e1–240.e12. [CrossRef] [PubMed]

73. Cressatti, M.; Juwara, L.; Galindez, J.M.; Velly, A.M.; Nkurunziza, E.S.; Marier, S.; Canie, O.; Gornistky, M.; Schipper, H.M.; Salivary microR-153 and microR-223 Levels as Potential Diagnostic Biomarkers in Colon Cancer. *Curr. Pharm. Des.* 2017, 23, 1705–1709. [CrossRef] [PubMed]

74. Shu, Y.; Qian, J.; Wang, C. Aberrant expression of microRNA-132-3p and microRNA-146a-5p in Parkinson’s disease patients. *Open Life Sci.* 2020, 15, 647–653. [CrossRef] [PubMed]

75. Yang, Z.; Li, T.; Li, S.; Wei, M.; Qi, H.; Shen, B.; Chang, R.C.; Le, W.; Piao, F. Altered Expression Levels of microRNA-132 and Nurr1 in Peripheral Blood of Parkinson’s Disease: Potential Disease Biomarkers. *ACS Chem. Neurosci.* 2019, 10, 2243–2249. [CrossRef]

76. Xu, Y.; Yang, Z.; Cui, Y.; Li, S.; Cheng, C.; Shen, B.; Le, W. Elevated Plasma microRNA-105-5p Level in Patients with Idiopathic Parkinson’s Disease: A Potential Disease Biomarker. *Front. Neurosci.* 2019, 13, 218. [CrossRef]

77. Yang, Z.; Li, T.; Cui, Y.; Li, S.; Cheng, C.; Shen, B.; Le, W. Elevated Plasma microRNA-105-5p Level in Patients with Idiopathic Parkinson’s Disease: A Potential Disease Biomarker. *Front. Neurosci.* 2019, 13, 218. [CrossRef]

78. Ozdilek, B.; Demircan, B. Serum microRNA expression levels in Turkish patients with Parkinson’s disease. *Int. J. Neurosci.* 2020, 131, 1181–1189. [CrossRef]
79. Grossi, I.; Radeghieri, A.; Paolini, L.; Porrini, V; Pilotto, A.; Padovani, A.; Marengoni, A.; Barbon, A.; Bellucci, A.; Pizzi, M.; et al. microRNA-34a-5p expression in the plasma and in its extracellular vesicle fractions in subjects with Parkinson’s disease: An exploratory study. *Int. J. Mol. Med.** 2021, 47, 533–546. [CrossRef]

80. Wu, Q.; Xi, D.Z.; Wang, Y.H. microRNA-599 regulates the development of Parkinson’s disease through mediating LRRK2 expression. *Eur. Rev. Med. Pharmacol. Sci.* **2019**, 23, 724–731.

81. Caggiu, E.; Paulus, K.; Mameli, G.; Arru, G.; Sechi, G.P.; Sechi, L.A. Differential expression of miRNA 155 and miRNA 146a in Parkinson’s disease patients. *Eur. Neuroligsci* **2018**, 13, 1–4. [CrossRef] [PubMed]

82. Thome, A.D.; Harms, A.S.; Volpicelli-Daley, L.A.; Standaert, D.G. microRNA-155 Regulates Alpha-Synuclein-Induced Inflammatory Responses in Models of Parkinson Disease. *J. Neurosci.* **2016**, 36, 2383–2390. [CrossRef] [PubMed]

83. Lv, R.; Du, L.; Liu, X.; Zhou, F.; Zhang, Z.; Zhang, L. Rosmarinic acid attenuates inflammatory responses through inhibiting HMGB1/TLR4/NF-κB signaling pathway in a mouse model of Parkinson’s disease. *Life Sci.* **2019**, 223, 158–165. [CrossRef] [PubMed]

84. Zhu, J.; Wang, S.; Qi, W.; Xu, X.; Liang, Y. Overexpression of miR-153 promotes oxidative stress in MPP(+) -induced PD model by negatively regulating the Nrf2/ HO-1 signaling pathway. *Int. J. Clin. Exp. Pathol.** 2018*, 11, 4179–4187.

85. Chiu, C.C.; Yeh, T.H.; Chen, R.S.; Chen, H.C.; Huang, Y.Z.; Weng, Y.H.; Cheng, Y.C.; Liu, Y.C.; Cheng, A.J.; Lu, Y.C.; et al. Upregulated Expression of microRNA-204-5p Leads to the Death of Dopaminergic Cells by Targeting Dyrk1A-Mediated Apoptotic Signaling Cascade. *Front. Cell. Neurosci.* **2019**, 13, 399. [CrossRef]

86. Radad, K.; Rausch, W.D.; Gille, G. Rotenone induces cell death in primary dopaminergic culture by increasing ROS production and inhibiting mitochondrial respiration. *Neurochem. Int.* **2006**, 49, 379–386. [CrossRef]

87. Jauhari, A.; Singh, T.; Mishra, S.; Shankar, J.; Yadav, S. Coordinated Action of miR-146a and Parkin Gene Regulate Rotenone-Induced Neurodegeneration. *Toxicol. Sci.* **2020**, 176, 433–445. [CrossRef]

88. Yu, A.; Zhang, T.; Zhong, W.; Duan, H.; Wang, S.; Ye, P.; Wang, J.; Zhong, S.; Yang, Z. miRNA-144 induces microglial autophagy and inflammation following intracerebral hemorrhage. *Immunol. Lett.* **2017**, 182, 18–23. [CrossRef]

89. Li, K.; Zhang, J.; Ji, C.; Wang, L. MiR-144-3p and Its Target Gene β- Amyloid Precursor Protein Regulate 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Induced Mitochondrial Dysfunction. *Mol. Cells** 2016*, 39, 543–549. [CrossRef]

90. Decressac, M.; Mattsson, B.; Weikop, P.; Lundblad, M.; Jakobsson, J.; Björklund, A. TFEB-mediated autophagy rescues midbrain dopaminergic neurons from α-synuclein toxicity. *Proc. Natl. Acad. Sci. USA** 2013*, 110, E1817–E1826. [CrossRef]

91. Wang, R.; Yao, J.; Gong, F.; Chen, S.; He; Y.; Hu, C.; Li, C. MiR-29c-3p regulates TET2 expression and inhibits autophagy process in Parkinson’s disease models. *Genes Cells* **2021**, 26, 684–697. [CrossRef] [PubMed]

92. Nehammer, C.; Ejlerskov, P.; Gopal, S.; Handleby, A.; Ng, L.; Moreira, P.; Lee, H.; Issazadeh-Navikas, S.; Rubinsztein, D.C.; Pocock, R. Interferon-β-induced miR-1 alleviates toxic protein accumulation by controlling autophagy. *Elife* **2019**, 8, e49930. [CrossRef] [PubMed]

93. Ejlerskov, P.; Rubinsztein, D.C.; Pocock, R. IFNβ/interferon-β regulates autophagy via a MIR1-TBC1D15-RAB7 pathway. *Autophagy* **2020**, 16, 767–769. [CrossRef] [PubMed]

94. Zhao, X.H.; Wang, Y.B.; Yang, J.; Liu, H.Q.; Wang, L.L. microRNA-326 suppresses iNOS expression and promotes autophagy of dopaminergic neurons through the JNK signaling by targeting XBP1 in a mouse model of Parkinson’s disease. *J. Cell Biochem.** 2019*, 120, 14995–15006. [CrossRef] [PubMed]

95. Zhang, Y.; Xu, W.; Nan, S.; Chang, M.; Fan, J. microRNA-326 Inhibits Apoptosis and Promotes Proliferation of Dopaminergic Neurons in Parkinson’s Disease Through Suppression of KLK-Mediated MAPK Signaling Pathway. *J. Mol. Neurosci.* **2019**, 69, 197–214. [CrossRef]

96. Cai, Z.; Zheng, F.; Ding, Y.; Zhan, Y.; Gong, R.; Li, J.; Aschner, M.; Zhang, Q.; Wu, S.; Li, H. Nrf2-regulated miR-380-3p blocks the translation of Sp3 protein and its mediation of paraquat-induced toxicity in mouse neuroblastoma N2a cells. *Toxicol. Sci.* **2019**, 171, 515–529. [CrossRef]

97. Zhu, J.; Xu, X.; Liang, Y.; Zhu, R. Downregulation of microRNA-15b-5p Targeting the Akt3-Mediated GSK-3β/β-Catenin Signaling Pathway Inhibits Cell Apoptosis in Parkinson’s Disease. *Biomol. Res. Int.* **2021**, 2021, 8814862. [CrossRef]

98. Qin, X.; Zhang, X.; Li, P.; Wang, M.; Yan, L.; Pan, P.; Zhang, H.; Hong, X.; Liu, M.; Bao, Z. microRNA-185 activates PI3K/AKT signalling pathway to alleviate dopaminergic neuron damage via targeting IGF1 in Parkinson’s disease. *J. Drug Target* **2021**, 29, 875–883. [CrossRef]

99. Yu, F.; Le, Z.S.; Chen, L.H.; Qian, H.; Yu, B.; Chen, W.H. Identification of Biomolecular Information in Rotenone-Induced Cellular Model of Parkinson’s Disease by Public Microarray Data Analysis. *J. Comput. Biol.* **2020**, 27, 888–903. [CrossRef]

100. Qin, L.X.; Tan, J.Q.; Zhang, H.N.; Tang, J.G.; Jiang, B.; Shen, X.M.; Tang, B.S.; Wang, C.Y. Preliminary study of hsa-miR-626 change in the cerebrospinal fluid of Parkinson’s disease patients. *J. Clin. Neurosci.* **2019**, 70, 198–201. [CrossRef]

101. Uwatoko, H.; Hama, Y.; Iwata, I.T.; Shirai, S.; Matsushima, M.; Yabe, I.; Utsumi, J.; Sasaki, H. Identification of plasma microRNA expression changes in multiple system atrophy and Parkinson’s disease. *Mol. Brain* **2019**, 12, 49. [CrossRef] [PubMed]

102. Patil, K.S.; Basak, I.; Dalen, I.; Hoedt, E.; Lange, J.; Lunde, K.A.; Liu, Y.; Tysnes, O.B.; Forsgren, L.; Aarsland, D.; et al. Combinatory microRNA serum signatures as classifiers of Parkinson’s disease. *Parkinsonism Relat. Disord.* **2019**, 64, 202–210. [CrossRef] [PubMed]
104. Chatterjee, P.; Bhattacharyya, M.; Bandyopadhyay, S.; Roy, D. Studying the system-level involvement of microRNAs in Parkinson’s disease. *PLoS ONE* **2014**, *9*, e93751. [CrossRef]

105. Coccia, E.; Masanas, M.; López-Soriano, J.; Segura, M.F.; Comella, J.X.; Pérez-García, M.J. FAIM Is Regulated by MiR-206, MiR-1-3p and MiR-133b. *Front. Cell Dev. Biol.* **2020**, *8*, 584606. [CrossRef]

106. Su, Y.; Deng, M.F.; Xiong, W.; Xie, A.J.; Guo, J.; Liang, Z.H.; Hu, B.; Chen, J.G.; Zhu, X.; Man, H.Y.; et al. microRNA-26a/Death-Associated Protein Kinase 1 Signaling Induces Synucleinopathy and Dopaminergic Neuron Degeneration in Parkinson’s Disease. *Biol. Psychiatry* **2019**, *85*, 769–781. [CrossRef]

107. Krammes, L.; Hart, M.; Rheinheimer, S.; Diener, C.; Menegatti, J.; Grässer, F.; Keller, A.; Meese, E. Induction of the Endoplasmic-Reticulum-Stress Response: microRNA-34a-5p targeting the IRE1α-Branch. *Cells* **2020**, *9*, 1442. [CrossRef]

108. Li, G.; Luo, W.; Wang, B.; Qian, C.; Ye, Y.; Li, Y.; Zhang, S. HMGA1 Induction of mir-103/107 Forms a Negative Feedback Loop to Regulate Autophagy in MPTP Model of Parkinson’s Disease. *Front. Cell Neurosci.* **2020**, *14*, 620020. [CrossRef]

109. Zhang, G.; Chen, L.; Liu, J.; Jin, Y.; Lin, Z.; Du, S.; Fu, Z.; Chen, T.; Qin, Y.; Sui, F.; et al. HIF-1α/microRNA-128-3p axis protects hippocampal neurons from apoptosis via the Axin1-mediated Wnt/β-catenin signaling pathway in Parkinson’s disease models. *Aging (Albany NY)* **2020**, *12*, 4067–4081. [CrossRef]

110. Yao, L.; Zhu, Z.; Wu, J.; Zhang, Y.; Zhang, H.; Sun, X.; Qian, C.; Wang, B.; Xie, L.; Zhang, S.; et al. microRNA-124 regulates the expression of p62/p38 and promotes autophagy in the inflammatory pathogenesis of Parkinson’s disease. *Front. Cell Dev. Biol.* **2020**, *8*, e922032. [CrossRef] [PubMed]

111. Xing, R.X.; Li, L.G.; Liu, X.W.; Tian, B.X.; Cheng, Y. Down regulation of miR-218, miR-124, and miR-144 relates to Parkinson’s disease via activating NF-kB signaling. *Kaohsiung J. Med. Sci.* **2020**, *36*, 786–792. [CrossRef]

112. He, Q.; Wang, Q.; Yuan, C.; Wang, Y. Downregulation of miR-7116-5p in microglia by MPP(+) sensitizes TNF-α production to induce dopaminergic neuron damage. *Glia* **2017**, *65*, 1251–1263. [CrossRef]
128. Zhou, Y.; Lu, M.; Du, R.H.; Qiao, C.; Jiang, C.Y.; Zhang, K.Z.; Ding, J.H.; Hu, G. microRNA-7 targets Nod-like receptor protein 3 in inflammasome to modulate neuroinflammation in the pathogenesis of Parkinson’s disease. Mol. Neurodegener. 2016, 11, 28. [CrossRef]

129. Karic, A.; Terzic, R.; Karic, A.; Peterlin, B. Identifying candidate genes for Parkinson’s disease by integrative genomics method. Biochem. Med. 2011, 21, 174–181. [CrossRef]

130. Zhang, J.; Liu, W.; Wang, Y.; Zhao, S.; Chang, N. miR-135b Plays a Neuroprotective Role by Targeting GSK3beta in MPP(+) Intoxicated SH-SY5Y Cells. Dis. Markers 2017, 2017, 8860146. [CrossRef]

131. Li, X.Q.; Chen, F.S.; Tan, W.F.; Fang, B.; Zhang, Z.L.; Ma, H. Elevated microRNA-129-5p level ameliorates neuroinflammation and blood-spinal cord barrier damage after ischemia-reperfusion by inhibiting HMG1 and the TLR3-cytokine pathway. J. Neuroinflamm. 2017, 14, 205. [CrossRef] [PubMed]

132. Cui, H.; Xu, Z.; Qu, C. Tetramethylpyrazine ameliorates isoflurane-induced cognitive dysfunction by inhibiting neuroinflammation via miR-150 in rats. Exp. Ther. Med. 2020, 20, 3878–3887. [CrossRef]

133. Li, H.; Yu, L.; Li, M.; Chen, X.; Tian, Q.; Jiang, Y.; Li, N. microRNA-150 serves as a diagnostic biomarker and is involved in the inflammatory pathogenesis of Parkinson’s disease. Mol. Genet. Genom. Med. 2020, 8, e1189. [CrossRef]

134. Wang, M.; Sun, H.; Yao, Y.; Tang, X.; Wu, B. microRNA-217/138-5p downregulation inhibits inflammatory response, oxidative stress and the induction of apoptosis in MPP(+) -intoxicated SH-SY5Y cells. Am. J. Transl. Res. 2019, 11, 6619–6631. [CrossRef]

135. Cho, H.J.; Liu, G.; Jin, S.M.; Parisiadou, L.; Xie, C.; Yu, J.; Sun, L.; Ma, B.; Ding, J.; Vancraenenbroeck, R.; et al. microRNA-205 regulates the expression of Parkinson’s disease-related leucine-rich-repeat kinase 2 protein. Hum. Mol. Genet. 2013, 22, 608–620. [CrossRef] [PubMed]

136. Cai, L.J.; Tu, L.; Li, T.; Yang, X.L.; Ren, Y.P.; Gu, R.; Zhang, Q.; Yao, H.; Qu, X.; Wang, Q.; et al. Up-regulation of microRNA-375 ameliorates the dopamine neurons, reduces oxidative stress and inflammation in Parkinson’s disease by inhibiting SIP1. Aging (Albany NY) 2020, 12, 672–689. [CrossRef] [PubMed]

137. Mao, H.; Ding, L. Downregulation of miR-21 suppresses 1-methyl-4-phenylpyridinium-induced neuronal damage in MES23.5 cells. Exp. Ther. Med. 2019, 18, 2467–2474. [CrossRef]

138. Lv, Q.; Zhong, Z.; Hu, B.; Yan, S.; Yan, Y.; Zhang, J.; Shi, T.; Jiang, L.; Li, W.; Huang, W. microRNA-3473b regulates the expression of TREM2/ULK1 and inhibits autophagy in inflammatory pathogenesis of Parkinson disease. J. Neurochem. 2021, 157, 599–610. [CrossRef]

139. Sun, X.; Sun, J.; Shao, X.; Feng, J.; Yan, J.; Qin, Y. Inhibition of microRNA-155 modulates endotoxin tolerance by upregulating suppressor of cytokine signaling 1 in microglia. Exp. Ther. Med. 2018, 15, 4709–4716. [CrossRef]

140. Martin, N.A.; Molnar, V.; Szilagyi, G.T.; Elkjaer, M.L.; Nawrocki, A.; Okarmus, J.; Wlodarczyk, A.; Thygesen, E.K.; Palkovits, M.; Gallyas, F., Jr.; et al. Experimental Demyelination and Axonal Loss Are Reduced in microRNA-146a Deficient Mice. Front. Immunol. 2018, 9, 490. [CrossRef]

141. Zhang, X.D.; Fan, Q.Y.; Qiu, Z.; Chen, S. MiR-7 alleviates secondary inflammatory response of microglia caused by cerebral hemorrhage through inhibiting TLR4 expression. Eur. Rev. Med. Pharmacol. Sci. 2018, 22, 5597–5604. [PubMed]

142. Choi, D.C.; Yoo, M.; Kabaria, S.; Junn, E. microRNA-7 facilitates the degradation of alpha-synuclein and its aggregates by promoting autophagy. Neurosci. Lett. 2018, 678, 118–123. [CrossRef] [PubMed]

143. McMillan, K.J.; Murray, T.K.; Bengoa-Vergniory, N.; Cordero-Llana, O.; Cooper, J.; Buckley, A.; Wade-Martins, R.; Uney, J.B.; O’Neill, M.J.; Wong, L.F.; et al. microRNA-155 Regulation Leads to alpha-Synuclein Accumulation and Dopaminergic Neuronal Loss In Vivo. Mol. Ther. J. Am. Soc. Gene Ther. 2017, 25, 2404–2414. [CrossRef] [PubMed]

144. Feng, Y.; Li, T.; Xing, C.; Wang, C.; Duan, Y.; Yuan, L.; Zhang, Y. Effective inhibition of miR-330/SHPII/NF-κB signaling pathway via mi-R-330 sponge polarizes microglia differentiation. Cell Biol. Int. 2021, 45, 785–794. [CrossRef] [PubMed]

145. Zhang, J.; Dongwei, Z.; Zhang, Z.; Xinhui, Q.; Kunwang, B.; Guohui, L.; Jian, D. miR-let-7a suppresses α-Synuclein-induced microglia inflammation through targeting STAT5 in Parkinson’s disease. Biochem. Biophys. Res. Commun. 2019, 519, 740–746. [PubMed]

146. Feng, Y.; Zheng, C.; Zhang, Y.; Xing, C.; Cai, W.; Li, R.; Chen, J.; Duan, Y. Triptolide Inhibits Preformed Fibril-Induced Microglial Activation by Targeting the microRNA155-5p/SHPII Pathway. Oxid. Med. Cell Longev. 2019, 2019, 6527638. [CrossRef]

147. Aliev, A.; Filatova, E.V.; Karabanov, A.V.; Ilarioshkin, S.N.; Limborska, S.A.; Shadrina, M.I.; Slominsky, P.A. miRNA expression is highly sensitive to a drug therapy in Parkinson’s disease. Parkinsonism Relat. Disord. 2015, 21, 72–74. [CrossRef]

148. Chis, A.R.; Moatar, A.L.; Dijmarence, C.; Rosca, C.; Vorovenci, R.J.; Krabbendam, L.; Dolga, A.; Bejinar, C.; Marian, C.; Sirbu, I.O.; et al. Plasma hsa-miR-19b is a potential LevoDopa therapy marker. Clin. Exp. Ther. Med. 2018, 45, 68–74. [CrossRef]

149. Wang, X.; Liu, Z.; Wang, F. microRNA-93 Blocks Signal Transducers and Activator of Transcription 3 to Reduce Neuronal Damage in Parkinson’s Disease. Neurochem. Res. 2021, 46, 1859–1866. [CrossRef]

150. Yang, Z.; Xu, J.; Zhu, R.; Liu, L. Down-Regulation of miRNA-128 Contributes to Neuropathic Pain Following Spinal Cord Injury via Activation of P38. Mol. Sci. Monit. 2017, 23, 405–411. [CrossRef] [PubMed]

151. Li, X.Q.; Chen, F.S.; Tan, W.F.; Fang, B.; Zhang, Z.L.; Ma, H. Correction to: Elevated microRNA-129-5p level ameliorates neuroinflammation and blood-spinal cord barrier damage after ischemia-reperfusion by inhibiting HMG1 and the TLR3-cytokine pathway. J. Neuroinflamm. 2021, 18, 308. [CrossRef] [PubMed]
153. Zeng, R.; Luo, D.X.; Li, H.P.; Zhang, Q.S.; Lei, S.S.; Chen, J.H. microRNA-135b alleviates MPP(+)‐mediated Parkinson’s disease in an in vitro model through suppressing FoxO1‐induced NLRP3 inflammasome and pyroptosis. J. Clin. Neurosci. 2019, 65, 125–133. [CrossRef] [PubMed]

154. Peng, T.; Liu, X.; Wang, J.; Liu, Y.; Fu, Z.; Ma, X.; Li, J.; Sun, G.; Ji, Y.; Lu, J.; et al. Long noncoding RNA HAGLROS regulates apoptosis and autophagy in Parkinson’s disease via regulating miR‐100/ATG10 axis and PI3K/Akt/mTOR pathway activation. Artif. Cells Nanomed. Biotechnol. 2019, 47, 2764–2774. [CrossRef]

155. Huarte, M. The emerging role of IncRNAs in cancer. Nat. Med. 2015, 21, 1253–1261. [CrossRef]

156. Li, Q.; Wang, Z.; Xing, H.; Wang, Y.; Guo, Y. Exosomes derived from miR‐188‐3p‐modified adipose‐derived mesenchymal stem cells protect Parkinson’s disease. Mol. Nucleic. Acids 2021, 23, 1334–1344. [CrossRef]

157. Sun, Q.; Wang, S.; Chen, J.; Cai, H.; Huang, W.; Zhang, Y.; Wang, L.; Xing, Y. microRNA‐190 alleviates neuronal damage and inhibits neuroinflammation via Nlrp3 in MPTP‐induced Parkinson’s disease mouse model. J. Cell Physiol. 2019, 234, 23379–23387. [CrossRef]

158. Xia, L.; Zhang, Y.; Dong, T. Inhibition of microRNA‐221 Alleviates Neuropathic Pain Through Targeting Suppressor of Cytokine Signaling 1. J. Mol. Neurosci. 2016, 59, 411–420. [CrossRef]

159. Li, L.; Xu, J.; Wu, M.; Hu, J.M. Protective role of microRNA‐221 in Parkinson’s disease. Bratisl. Lek. Listy 2018, 119, 22–27. [CrossRef]

160. Song, Z.; Xie, B. LncRNA OIP5‐AS1 reduces 

161. Lang, Y.; Li, Y.; Yu, H.; Lin, L.; Chen, X.; Wang, S.; Zhang, H. HOTAIR drives autophagy in midbrain dopaminergic neurons in the e93–e103. [CrossRef] [PubMed]

162. Yan, W.; Chen, Z.Y.; Chen, J.Q.; Chen, H.M. LncRNA NEAT1 promotes autophagy in MPTP‐induced Parkinson’s disease through stabilizing PINK1 protein. Biochem. Biophys. Res. Commun. 2018, 496, 1019–1024. [CrossRef] [PubMed]

163. Zhao, J.; Li, H.; Chang, N. LncRNA HOTAIR promotes MPP+‐induced neuronal injury by regulating the miR‐124/KLF4 axis in Parkinson’s disease. Mol. Neurobiol. 2015, 49, 119–127. [CrossRef]

164. Boros, F.A.; Maszlag‐Török, R.; Vécei, L.; Klivényi, P. Increased level of NEAT1 long non‐coding RNA is detectable in peripheral blood cells of patients with Parkinson’s disease. Brain Res. 2020, 1730, 146672. [CrossRef] [PubMed]

165. Simchovitz, A.; Hanan, M.; Niederhofer, N.; Madrer, N.; Yayon, N.; Bennett, E.R.; Greenberg, D.S.; Kadener, S.; Soreq, H. NEAT1 is overexpressed in Parkinson’s disease substantia nigra and confers drug‐inducible neuroprotection from oxidative stress. Faseb. J. 2019, 33, 11223–11234. [CrossRef]

166. Lin, Q.; Hou, S.; Dai, Y.; Jiang, N.; Lin, Y. LncRNA Hotair targets miR‐126‐5p to promote the progression of Parkinson’s disease through RAB3IP. Biol. Chem. 2019, 400, 1217–1228. [CrossRef]

167. Fan, Y.; Zhao, X.; Lu, K.; Cheng, G. LncRNA BDNF‐AS promotes autophagy and apoptosis in mptp‐induced Parkinson’s disease via ablating microRNA‐125b‐5p. Brain Res. Bull. 2020, 157, 119–127. [CrossRef]

168. Wang, L.; Sun, Q.; Xiong, B.; Zhang, L.; Yu, X.; Ouyang, X. Long Noncoding RNA NEAT1 Knockdown Ameliorates 1‐Methyl‐4‐Phenylpyridine‐Induced Cell Injury Through microRNA‐519a‐3p/SP1 Axis in Parkinson Disease. World Neurosurg. 2021, 156, e93–e103. [CrossRef] [PubMed]

169. Liu, T.; Zhang, Y.; Liu, W.; Zhao, J. LncRNA NEAT1 Regulates the Development of Parkinson’s Disease by Targeting AXIN1 Via Sponging miR‐212‐3p. J. Cell Physiol. 2019, 234, 23379–23387. [CrossRef]
Lun, P.; Ji, T.; Wan, D.H.; Liu, X.; Chen, X.D.; Yu, S.; Sun, P. HOTTIP downregulation reduces neuronal damage and microglial activation in Parkinson’s disease cell and mouse models. *Neural. Regen. Res.* 2022, 17, 887–897. [PubMed]  

Zheng, Y.; Liu, J.; Zhuang, J.; Dong, X.; Yu, M.; Li, Z. Silencing of UCA1 Protects Against MPP+-Induced Cytotoxicity in SH-SY5Y Cells. *Neurochem. Res.* 2021, 46, 3286–3300. [CrossRef]  

Han, Y.; Kang, C.; Kang, M.; Quan, W.; Gao, H.; Zhong, Z. Long non-coding RNA Mirt2 prevents TNF-α-triggered inflammation via the repression of microRNA-375. *Int. Immunopharmacol.* 2019, 76, 105878. [CrossRef] [PubMed]  

Lun, P.; Ji, T.; Wan, D.H.; Liu, X.; Chen, X.D.; Yu, S.; Sun, P. HOTTIP downregulation reduces neuronal damage and microglial activation in Parkinson’s disease model by targeting the miR-425-5p/TRA5/FB15-Kβ axis. *Biochem. Mol. Toxicol.* 2021, 35, e22867. [CrossRef] [PubMed]  

Zhang, H.; Wang, Z.; Hu, K.; Liu, H. Downregulation of long noncoding RNA SNHG7 protects against inflammation and apoptosis in Parkinson’s disease model via the miR-29c-3p-mediated AMPK/mTOR pathway in Parkinson’s disease. *Hum. Gene Ther.* 2020, 31, 1017–1030. [CrossRef] [PubMed]  

L’Episcopo, F.; Tirolo, C.; Testa, N.; Caniglia, S.; Morale, M.C.; Serapide, M.F.; Pluchino, S.; Marchetti, B. Wnt/β-catenin signaling is required to rescue midbrain dopaminergic progenitors and promote neurorepair in ageing mouse model of Parkinson’s disease. *Stem Cells* 2014, 32, 2147–2163. [CrossRef]  

Jiang, J.; Piao, X.; Hu, S.; Gao, J.; Bao, M. LncRNA H19 diminishes dopaminergic neuron loss by mediating microRNA-301b-3p in Parkinson’s disease via the HPRT1-mediated Wnt/β-catenin signaling pathway. *Aging (Albany NY)* 2020, 12, 8820–8836. [CrossRef] [PubMed]  

Zhang, Y.; Xia, Q.; Lin, J. LncRNA H19 Attenuates Apoptosis in MPTP-Induced Parkinson’s Disease Through Regulating miR-585-3p/PIK3R3. *Neurochem. Res.* 2020, 45, 1700–1710. [CrossRef] [PubMed]  

Long, L.; Zeng, C.; Chen, H.; Zhou, T.; Wu, L.; Cai, X. ADNCR modulates neural stem cell differentiation and proliferation through the regulation of TCF3 expression. *Ann. Transl. Med.* 2020, 8, 927. [CrossRef] [PubMed]  

Zhang, Q.; Huang, X.M.; Liao, J.X.; Dong, Y.K.; Zhu, J.L.; He, C.C.; Huang, J.; Tang, Y.W.; Wu, D.; Tian, J.Y. LncRNA HOTAIR Promotes Neuronal Damage Through Facilitating NLRP3-Mediated-Pyroptosis Activation in Parkinson’s Disease via Regulation of miR-326/EVAA1 Axis. *Cell Mol. Neurobiol.* 2021, 41, 1773–1786. [CrossRef]  

Li, Y.; Fang, J.; Zhou, Z.; Zhou, Q.; Sun, S.; Jin, Z.; Xi, Z.; Wei, J. Downregulation of IncRNA BACE1-AS improves dopamine-dependent oxidative stress in rats with Parkinson’s disease by upregulating microRNA-34b-5p and downregulating BACE1. *Cell Cycle* 2020, 19, 1158–1171. [CrossRef] [PubMed]  

Zheng, Y.; Liu, J.; Zhuang, J.; Dong, X.; Yu, M.; Li, Z. Silencing of UCA1 Protects Against MPP+-Induced Cytotoxicity in SK-N-SH Cells via Modulating miR-122b-5p and miR-129-5p/RAB3IP axis. *Biochem. Biophys. Res. Commun.* 2020, 522, 388–394. [CrossRef] [PubMed]  

Wang, W.; Lv, R.; Zhang, J.; Liu, Y. circSAMD4A participates in the apoptosis and autophagy of dopaminergic neurons via the miR-29c-3p-mediated AMPK/mTOR pathway in Parkinson’s disease. *Mol. Med. Rep.* 2021, 24, 540. [CrossRef] [PubMed]
202. Kumar, L.; Shamsuzzaman; Jadiya, P.; Haque, R.; Shukla, S.; Nazir, A. Functional Characterization of Novel Circular RNA Molecule, circzip-2 and Its Synthesizing Gene zip-2 in C. elegans Model of Parkinson’s Disease. *Mol. Neurobiol.* 2018, 55, 6914–6926. [CrossRef]

203. Hanan, M.; Simchovitz, A.; Yayon, N.; Vaknine, S.; Cohen-Fullheim, R.; Karmon, M.; Madrer, N.; Rohrlich, T.M.; Maman, M.; Bennett, E.R.; et al. A Parkinson’s disease circRNAs Resource reveals a link between circSLC8A1 and oxidative stress. *EMBO Mol. Med.* 2020, 12, e1942. [CrossRef]

204. Cao, X.; Guo, J.; Mochizuki, H.; Xu, D.; Zhang, T.; Han, H.; Ma, T.; Qi, M.; He, J. Circular RNA circ_0070411 regulates MPP(+)‐triggered neurotoxic effect in SH-SYSY cells via miR-626/IR52 axis. *Metab. Brain Dis.* 2021, 37, 513–524. [CrossRef] [PubMed]

205. Soares, E.; Reis, J.; Rodrigues, M.; Ribeiro, C.F.; Pereira, F.C. Circulating Extracellular Vesicles: The Missing Link between Physical Exercise and Depression Management? *Int. J. Mol. Sci.* 2021, 22, 542. [CrossRef] [PubMed]

206. Hanan, M.; Simchovitz, A.; Yayon, N.; Vaknine, S.; Cohen-Fultheim, R.; Karmon, M.; Madrer, N.; Rohrlich, T.M.; Maman, M.; Bennett, E.R.; et al. A Parkinson’s disease circRNAs Resource reveals a link between circSLC8A1 and oxidative stress. *EMBO Mol. Med.* 2020, 12, e1942. [CrossRef]

207. Doxakis, E. Cell-free microRNAs in Parkinson’s disease: Potential biomarkers that provide new insights into disease pathogenesis. *Aging Res. Rev.* 2020, 58, 101032. [CrossRef]

208. Ravanidis, S.; Bougea, A.; Papagiannakis, N.; Maniatis, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

209. Chen, Q.; Deng, N.; Lu, K.; Liao, Q.; Long, X.; Gou, D.; Bi, F.; Zhou, J. Elevated plasma miR-133b and miR-221-3p as biomarkers for early Parkinson’s disease. *Sci. Rep.* 2021, 11, 15268. [CrossRef]

210. Akbari, M.; Gholipour, M.; Hussen, B.M.; Taheri, M.; Esfasi, S.; Sayad, A.; Ghafouri-Fard, S. Expression of BDNF-Associated IncRNAs in Parkinson’s disease. *Metab. Brain Dis.* 2022, 37, 901–909. [CrossRef] [PubMed]

211. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleinjans, J.C.S.; Prickaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

212. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

213. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleinjans, J.C.S.; Prickaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

214. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleinjans, J.C.S.; Prickaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

215. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleinjans, J.C.S.; Prickaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

216. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleinjans, J.C.S.; Prickaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

217. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briedé, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

218. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

219. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

220. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

221. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

222. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

223. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

224. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]

225. Van den Berg, M.M.J.; Krauskopf, J.; Ramaekers, J.G.; Kleijnen, J.C.S.; Prckaerts, J.; Briede, J.J. Circulating microRNAs as potential biomarkers for psychiatric and neurodegenerative disorders. *Prog. Neurobiol.* 2020, 185, 101732. [CrossRef] [PubMed]
Pharmaceuticals 2022, 15, 811

226. Jiang, X.; Xiao, L.; Jiang, X.; Li, G.; Lu, Z. Screening of Parkinson’s Differential microRNA Based on GEO Database and Its Clinical Verification. Biomed. Res. Int. 2021, 2021, 8171236. [CrossRef]

227. Mannia, I.; Quattrocchi, A.; De Benedittis, S.; Vescio, B.; Jaccino, E.; Quattrocchi, A. Exosomal miRNA as peripheral biomarkers in Parkinson’s disease and progressive supranuclear palsy: A pilot study. Parkinsonism Relat. Disord. 2021, 93, 77–84. [CrossRef]

228. Li, L.; Ren, J.; Fan, C.; Li, Y.; Xu, J.; Dong, H.; Chen, Y.; Liu, W. Serum miR-214 Serves as a Biomarker for Prodomal Parkinson’s Disease. Front. Aging Neurosci. 2021, 13, 709599. [CrossRef]

229. He, S.; Huang, L.; Shao, C.; Nie, T.; Xia, L.; Cui, B.; Lu, F.; Zhu, L.; Chen, B.; Yang, Q. Several miRNAs derived from serum extracellular vesicles are potential biomarkers for early diagnosis and progression of Parkinson’s disease. Transl. Neurodegener. 2021, 10, 25. [CrossRef]

230. Nie, C.; Sun, Y.; Zhen, H.; Guo, M.; Ye, J.; Liu, Z.; Yang, Y.; Zhang, X. Differential Expression of Plasma Exo-miRNA in Neurodegenerative Diseases by Next-Generation Sequencing. Front. Neurosci. 2020, 14, 438. [CrossRef] [PubMed]

231. Ravanidis, S.; Bougea, A.; Papagiannakis, N.; Koros, C.; Simitsi, A.M.; Pachi, I.; Breza, M.; Stefanis, L.; Doxakis, E. Validation of differentially expressed brain-enriched miRNAs in the plasma of PD patients. Ann. Clin. Transl. Neurol. 2020, 7, 1594–1607. [CrossRef] [PubMed]

232. Qin, L.X.; Tan, J.Q.; Zhang, H.N.; Tang, J.G.; Jiang, B.; Shen, X.M.; Guo, J.F.; Tan, L.M.; Zhang, B.; Wang, C.Y. Preliminary Study of hsa-mir-626 Change in the Cerebrospinal Fluid in Parkinson’s Disease. Neurol. India 2021, 69, 115–118. [CrossRef] [PubMed]

233. Jiang, Y.; Chen, J.; Sun, Y.; Li, F.; Wei, L.; Sun, W.; Deng, J.; Yuan, Y.; Wang, Z. Profiling of Differentially Expressed microRNAs in Saliva of Parkinson’s Disease Patients. Front. Neurosci. 2021, 12, 738530. [CrossRef]

234. Sanger, H.L.; Klotz, G.; Riesner, D.; Gross, H.J.; Kleinschmidt, A.K. Viroids are single-stranded covalently closed circular RNA molecules existing as highly base-paired rod-like structures. Proc. Natl. Acad. Sci. USA 1976, 73, 3852–3856. [CrossRef]

235. Chen, L.L. The biogenesis and emerging roles of circular RNAs. Nat. Rev. Mol. Cell Biol. 2016, 17, 205–211. [CrossRef]

236. Li, Y.; Zheng, Q.; Bao, C.; Li, S.; Guo, W.; Zhao, J.; Chen, D.; Gu, J.; He, X.; Huang, S. Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosis. Cell Res. 2015, 25, 981–984. [CrossRef]

237. Kristensen, L.S.; Andersen, M.S.; Stagsted, L.V.W.; Ebbe, K.K.; Hansen, T.B.; Kjems, J. The biogenesis, biology and characterization of circular RNAs. Nat. Rev. Genet. 2019, 20, 675–691. [CrossRef]

238. Patop, I.L.; Wüst, S.; Kadener, S. Past, present, and future of circRNAs. EMBO J. 2019, 38, e100836. [CrossRef]

239. Kong, F.; Lv, Z.; Wang, L.; Zhang, K.; Cai, Y.; Ding, Q.; Sun, Z.; Zhen, H.; Jiao, F.; Ma, Q.; et al. RNA-sequencing of peripheral blood circular RNAs in Parkinson disease. Medicine 2021, 100, e25888. [CrossRef]

240. Ravanidis, S.; Bougea, A.; Karampatsi, D.; Papagiannakis, N.; Maniati, M.; Stefanis, L.; Doxakis, E. Differentially Expressed Circular RNAs in Peripheral Mononuclear Cells of Patients with Parkinson’s Disease. Mov. Disord. 2021, 36, 1170–1179. [CrossRef] [PubMed]

241. Yang, L.; Han, X.; Zhang, C.; Sun, C.; Huang, S.; Xiao, W.; Gao, Y.; Liang, Q.; Luo, F.; Lu, W.; et al. Hsa_circ_0060450 Negatively Regulates Type I Interferon-Induced Inflammation by Serving as miR-199a-5p Sponge in Type 1 Diabetes Mellitus. Front. Immunol. 2020, 11, 576903. [CrossRef]

242. Shen, L.; Hu, Y.; Lou, J.; Yin, S.; Wang, W.; Wang, Y.; Xia, Y.; Wu, W. circRNA-0044073 is upregulated in atherosclerosis and increases the proliferation and invasion of cells by targeting miR-107. Mol. Med. Rep. 2019, 19, 3923–3932. [CrossRef]

243. Yuan, X.; Zhang, Y.; Cai, C.; Liu, C.; Xie, J.; Yi, C. Circular RNA circZNF652 is overexpressed in osteoarthritis and positively regulates LPS-induced apoptosis of chondrocytes by upregulating PTEN. Autoimmunity 2021, 54, 415–421. [CrossRef]

244. Chen, J.N.; Zhang, Y.N.; Tian, L.G.; Zhang, Y.; Li, X.Y.; Ning, B. Down-regulating Circular RNA Prkesh suppresses the inflammatory response after spinal cord injury. Neuro. Regen. Res. 2022, 17, 144–151. [CrossRef]

245. Hansen, T.B.; Jensen, T.I.; Clausen, B.H.; Bransum, B.; Finsen, B.; Damgaard, C.K.; Kjems, J. Natural RNA circles function as efficient microRNA sponges. Nature 2013, 495, 384–388. [CrossRef]

246. Rivetti di Val Cervo, P.; Romanov, R.A.; Spigolon, G.; Masini, D.; Martín-Montañez, E.; Toledo, E.M.; La Manno, G.; Feyder, M.; Pfii, C.; Ng, Y.H.; et al. Induction of functional dopamine neurons from human astrocytes in vitro and mouse astrocytes in a Parkinson’s disease model. Nat. Biotechnol. 2017, 35, 444–452. [CrossRef]

247. Javed, H.; Menon, S.A.; Al-Mansoori, K.M.; Al-Wandi, A.; Majbour, N.K.; Ardam, M.T.; Varghese, S.; Vaikath, N.N.; Haque, M.E.; Azzouz, M.; et al. Development of NonViral Vectors Targeting the Brain as a Therapeutic Approach for Parkinson’s Disease and Other Brain Disorders. Mol. Ther. 2016, 24, 746–758. [CrossRef]

248. Lowenstein, P.R.; Mandel, R.J.; Xiong, W.D.; Kroeger, K.; Castro, M.G. Immune responses to adenovirus and adeno-associated vectors used for gene therapy of brain diseases: The role of immunological synapses in understanding the cell biology of neuroimmune interactions. Curr. Gene Ther. 2007, 7, 347–360. [CrossRef]

249. Lundberg, C.; Björklund, T.; Carlsson, T.; Jakobsson, J.; Hantraye, P.; Dégon, N.; Kirik, D. Applications of lentiviral vectors for biology and gene therapy of neurological disorders. Curr. Gene Ther. 2008, 8, 461–473. [CrossRef]

250. Yin, H.; Kanasty, R.L.; Eltoukhy, A.A.; Vegas, A.J.; Dorkin, J.R.; Anderson, D.G. Non-viral vectors for gene-based therapy. Nat. Rev. Genet. 2014, 15, 541–555. [CrossRef]

251. Cooper, J.M.; Wiklander, P.B.; Nordin, J.Z.; Al-Shawi, R.; Wood, M.J.; Vithlani, M.; Schapira, A.H.; Simons, J.P.; El-Andaloussi, S.; Alvarez-Erviti, L. Systemic exosomal siRNA delivery reduced alpha-synuclein aggregates in brains of transgenic mice. Mov. Disord. 2014, 29, 1476–1485. [CrossRef]
252. Kojima, R.; Bojar, D.; Rizzi, G.; Hamri, G.C.; El-Baba, M.D.; Saxena, P.; Ausländer, S.; Tan, K.R.; Fussenegger, M. Designer exosomes produced by implanted cells intracerebrally deliver therapeutic cargo for Parkinson’s disease treatment. *Nat. Commun.* 2018, 9, 1305. [CrossRef]

253. Kalani, A.; Kamal, P.K.; Chaturvedi, P.; Tyagi, S.C.; Tyagi, N. Curcumin-primed exosomes mitigate endothelial cell dysfunction during hyperhomocysteinemia. *Life Sci.* 2014, 107, 1–7. [CrossRef]

254. Saraiva, C.; Paiva, J.; Santos, T.; Ferreira, L.; Bernardino, L. microRNA-124 loaded nanoparticles enhance brain repair in Parkinson’s disease. *J. Control. Release* 2016, 235, 291–305. [CrossRef]